




National Centre for  
Infectious Diseases



CHAPTER OF INFECTIOUS DISEASE PHYSICIANS  
COLLEGE OF PHYSICIANS, SINGAPORE

# Treatment Guidelines for COVID-19

(Version 10.1, dated 29 August 2022)

## ABSTRACT

### Background

In December 2019, a cluster of pneumonia cases caused by a novel coronavirus were reported in Wuhan, Hubei Province. Despite imposition by the China authorities of an unprecedented lockdown of Wuhan and other cities in Hubei province on 23 January 2020, cases within and outside China. On 11<sup>th</sup> March 2020, the World Health Organisation officially declared the outbreak of Coronavirus Disease 2019 (COVID-19) caused by the  $\beta$ -coronavirus “SARS-CoV-2” was a pandemic. As of 13 August 2022, the COVID-19 pandemic has led to over 590 million confirmed infections and more than 6.4 million deaths world-wide. This guideline provides updated evidence-based recommendations for the therapeutic management of patients with COVID-19 in Singapore, from our initial guidance issued on 2 April 2020.

### Methods

Published clinical trials, selected pre-print data, and where relevant in-vitro susceptibility data, and society and professional guidelines related to the treatment of COVID-19 till 2 August 2022 were reviewed. In previous iterations of this guidance, each recommendation was discussed and arrived at via consensus by the guideline committee, with the evidence behind each recommendation reviewed, and screened for conflicts of interest. In this current iteration, a modified Delphi method was used to achieve consensus for the updates. The committee first met to discuss to frame statements for the update, and in round one members individually provided their level of agreement with the statements using a 7-option Likert scale [Strongly agree, agree, somewhat agree, neither agree nor disagree, somewhat disagree, disagree, strongly disagree], and were free to provide comments for each statement. Consensus was set at 80% agreement [Strongly agree, agree, somewhat agree]. Results from round 1 were provided to members and statements not reaching consensus were then re-framed and shared with the panel in an iterative fashion till consensus was achieved.

## Summary of recommendations

### *Severe COVID-19*

1. Remdesivir may be considered for hospitalised patients who have severe COVID-19 (i.e. SpO<sub>2</sub> <94% on room air, requiring supplemental oxygen) in combination with steroids.
2. Dexamethasone (or equivalent steroid) is recommended for patients with severe COVID-19 (receipt of supplemental oxygen or mechanical ventilation).
3. Combination immune modulation with a JAK kinase inhibitor (e.g. Baricitinib) or IL-6 antagonist (e.g. Tocilizumab) should be considered in patients with severe COVID-19 with progressively worsening disease. Baricitinib may also be considered as an alternative to steroids and used in conjunction with remdesivir. Tocilizumab may be considered in patients who require high-flow or more intensive respiratory support and have features of hyperinflammation due to COVID-19.

### *Mild-moderate COVID-19*

4. In patients with mild-moderate COVID-19 with high risk for severe disease, monoclonal antibodies, remdesivir or the oral antivirals may be considered. Specific treatment choices may be guided by factors such as vaccination status and response (informed by antibody levels), treatment site (e.g. in hospital/treatment facilities versus home), and patient factors (e.g. risk stratification and suitability of particular treatments), virologic factors (activity of the agent considered against specific SARS-CoV-2 variants) and availability of such treatments.
  - a. The oral antiviral nirmatrelvir/ritonavir may be considered, for adult patients with mild to moderate COVID-19 at risk for severe disease, within 5 days of symptom onset. If there are contraindications to nirmatrelvir/ritonavir (e.g. drug-drug interactions which cannot be adjusted for, impaired renal function with a GFR <30 ml/min), and alternate therapies are not practicable, molnupiravir may be considered as an alternative.
  - b. Monoclonal antibodies (which have activity against circulating variants) may be considered for patients with mild to moderate COVID-19 who at high risk for severe disease, within 7 days of symptom onset. Given the emergence of Omicron, and other variants of concern (VOCs) efficacy of humoral therapies towards specific variants should be monitored, and the appropriate monoclonal antibody used.
  - c. Remdesivir may be considered in patients with mild to moderate COVID-19 who at high risk for severe disease within 7 days of symptom onset.

### *Anticoagulation*

5. Given the propensity for thromboembolic disease with COVID-19, pharmacologic prophylaxis should be considered in patients with severe or critical disease, or those who are elevated risk of thromboembolic disease (e.g. as stratified by a risk score such as the PADUA score), who do not have contraindications.

### *Other therapies*

6. We do not recommend as treatment or prophylaxis hydroxychloroquine, lopinavir/ritonavir, ivermectin, fluvoxamine, inhaled budesonide, favipiravir, interferon preparations, mesenchymal stem cell infusion or donor lymphocyte infusions, aspirin and other non-steroid immunomodulator therapies other than those recommended in this document at this time due to the lack of robust supporting data. Due to the availability of alternate humoral therapies (monoclonal antibodies), and the cessation of the national convalescent plasma programme for COVID-19, we do not recommend the use of convalescent plasma at this time.

## CONTENTS

Sections	Page
1. Overview	5
I) Key studies informing these therapeutic guidelines	6
II) Key changes since last interim guidance	9
2. Clinical Severity of COVID-19	10
3. Staging of COVID-19	10
4. Therapeutic recommendations for COVID-19	11
I) Level of recommendations	11
II) Treatment algorithm for COVID-19	12
III) Recommendations	
• Recommended Therapeutic management based on disease severity	12
• Pre-exposure Prophylaxis	26
• Post-exposure Prophylaxis	28
• Therapies that are not recommended or have insufficient evidence for recommendation	30
• Thromboprophylaxis and therapeutic anticoagulation to reduce disease progression and adverse clinical outcomes in COVID-19 patients	35
• Special populations: paediatric patients, pregnant women and immunocompromised hosts	37
6. Key drug summary table	49
Annex A: Data on various Monoclonal Antibodies (Mab) and activity against SARS-CoV-2	51
Annex B: Immunocompromise Definitions – following EC19V (Expert Committee on COVID-19 Vaccination)	53
Annex C: Algorithm for consideration of oral antivirals	54
Annex D: Managing Common Drug-Drug Interactions with Nirmatrelvir/Ritonavir (Paxlovid)	55
	60

### Versions

10.0 issued 27 August 2022 (addendum, 10.1 issued 29 August 2022)

9.0 issued 28 April 2022

8.0 issued 23 March 2022

7.0 issued 28 July 2021

6.0 issued 14 June 2021

5.0 issued 4 Jan 2021

4.0 issued 31 Aug 2020

3.0 issued 6 July 2020

2.0 issued 15 June 2020

1.0 issued 2 April 2020

## 1. Overview

SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA beta-coronavirus which causes COVID-19. Similar to SARS-CoV and MERS-CoV, SARS-CoV-2 infection may lead to severe respiratory disease.

Most patients with COVID-19 who are fully vaccinated against SARS-CoV-2 (i.e. up to date on vaccinations and recommended boosters) do not require specific treatment, and may be adequately managed with supportive care. Approximately 20% of patients with COVID-19 may progress to severe pneumonia and about 2-5% may require critical care. For this group of patients who progress to more severe disease, SARS-CoV-2 antivirals and/or immunomodulatory agents can be beneficial. For seronegative individuals SARS-CoV-2 monoclonal antibodies have also been shown to reduce the risk of progression.

Despite these advances, early supportive care and monitoring—including oxygen supplementation, organ support and prevention of complications—remain the cornerstone of clinical management of severe COVID-19.

The COVID-19 treatment guideline outlines pharmacologic treatment guidance for patients with COVID-19 in Singapore, and has undergone multiple updates with the accumulation of new evidence. Following our previous interim guidance, further data on monoclonal antibodies have been published or preliminarily reported. Key studies informing our recommendations are detailed in Box 1. Key changes from our last update are enumerated in Box 2.

## Box 1. Key studies informing these therapeutic guidelines

### Treatments for COVID-19

#### Dexamethasone and other steroids

RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with COVID-19. *N Engl J Med* 2021 Feb 25;384(8):693-704.

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *JAMA*. 2020 Oct 6;324(13):1330-1341. doi: 10.1001/jama.2020.17023. PMID: 32876694; PMCID: PMC7489434.

#### Remdesivir

Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med*. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8. PMID: 32445440; PMCID: PMC7262788.

Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. *N Engl J Med*. 2020 Nov 5;383(19):1827-1837.

Garibaldi BT, Wang K, Robinson ML, et al. Comparison of Time to Clinical Improvement with vs without Remdesivir Treatment in Hospitalized Patients with COVID-19. *JAMA Netw Open* 2021; 4:1–14.

Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. *Lancet* 2020; 395:1569-1578.

WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 2021 Feb 11;384(6):497-511.

Ader, F., Bouscambert-Duchamp, M., Hites, M., et al, & DisCoVeRy Study Group (2022). Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. *The Lancet. Infectious diseases*, 22(2), 209–221. [https://doi.org/10.1016/S1473-3099\(21\)00485-0](https://doi.org/10.1016/S1473-3099(21)00485-0)  
Gottlieb RL, Vaca CE, Paredes R, et al; GS-US-540-9012 (PINETREE) Investigators. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. *N Engl J Med*. 2021 Dec 22

#### Nirmatrelvir/Ritonavir

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *N Engl J Med*. 2022 Feb 16. doi: 10.1056/NEJMoa2118542. Epub ahead of print. PMID: 35172054.

Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. *N Engl J Med*. 2022 Aug 24. doi: 10.1056/NEJMoa2204919.

#### Molnupiravir

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quiros A, Caraco Y, Williams-Diaz A, Brown ML, Du J, Pedley A, Assaid C, Strizki J, Grobler JA, Shamsuddin HH, Tipping R, Wan H, Paschke A, Butterson JR, Johnson MG, De Anda C; MOVE-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. *N Engl J Med*. 2021 Dec 16;NEJMoa2116044. doi: 10.1056/NEJMoa2116044. Epub ahead of print. PMID: 34914868; PMCID: PMC8693688.

#### Baricitinib

Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *N Engl J Med* 2021 Mar 4;384(9):795-807.

Marconi VC, Ramanan AV, de Bono S, et al; COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. *Lancet Respir Med*. 2021 Dec;9(12):1407-1418.

Wesley EW, Ramanan AV, Kartman CE, et al; COV-BARRIER Study Group. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. *Lancet Respir Med*. 2022. Published online: February 03, 2022. DOI:[https://doi.org/10.1016/S2213-2600\(22\)00006-6](https://doi.org/10.1016/S2213-2600(22)00006-6)

**Tofacitinib**

Guimarães PO, Quirk D, Furtado RH, et al; STOP-COVID Trial Investigators. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. *N Engl J Med*. 2021 Jun 16. doi: 10.1056/NEJMoa2101643. PMID: 34133856.

**Tocilizumab**

Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. *Cochrane Database Syst Rev*. 2021 Mar 18;3:CD013881. doi: 10.1002/14651858.CD013881. PMID: 33734435.

RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0. PMID: 33933206; PMCID: PMC8084355

REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. *N Engl J Med* 2021 Apr 22;384(16):1491-1502.

Stone JH, Frigault MJ, Serling-Boyd NJ, et al; BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. *N Engl J Med*. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21. PMID: 33085857; PMCID: PMC7646626.

Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. *N Engl J Med* 2021; 384(1): 20-30.

**Tixagevimab/cilgavimab**

Montgomery H, Hobbs FDR, Padilla F, et al; TACKLE study group. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Respir Med*. 2022 Jun 7:S2213-2600(22)00180-1. doi: 10.1016/S2213-2600(22)00180-1. Epub ahead of print. PMID: 35688164; PMCID: PMC9173721.

ACTIV-3—Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Tixagevimab-cilgavimab for treatment of patients with COVID-19: a randomized, double-blind, phase 3 trial. *Lancet Respir Med*. 2022 Jul 8:S2213-2600(22)00215-6. Doi: 10.1016/S2213-2600(22)00215-6. Epub ahead of print. PMID: 35817072; PMCID: PMC9270059.

**Sotrivimab**

Gupta A, Gonzalez-Rojas Y, Juarez E, et al; COMET-ICE Investigators. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. *N Engl J Med*. 2021 Nov 18;385(21):1941-1950. doi: 10.1056/NEJMoa2107934. Epub 2021 Oct 27. PMID: 34706189.

Gupta A, Gonzalez-Rojas Y, Juarez E, et al; COMET-ICE Investigators. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. *JAMA*. 2022 Mar 14. doi: 10.1001/jama.2022.2832. Epub ahead of print. PMID: 35285853.

ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BR11-196 plus BR11-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. *Lancet Infect Dis*. 2021 Dec 23:S1473-3099(21)00751-9. doi: 10.1016/S1473-3099(21)00751-9. Epub ahead of print. PMID: 34953520; PMCID: PMC8700279.

**Prophylaxis**

O'Brien, M. P., Forleo-Neto, E., Musser, et al. Covid-19 Phase 3 Prevention Trial Team (2021). Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. *The New England journal of medicine*, 385(13), 1184–1195. <https://doi.org/10.1056/NEJMoa2109682>

Levin MJ, Ustianowski A, De Wit S, et al; PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. *N Engl J Med*. 2022 Jun 9;386(23):2188-2200. doi: 10.1056/NEJMoa2116620. Epub 2022 Apr 20. PMID: 35443106; PMCID: PMC9069994.

**Monoclonals – general**

Yamasoba D, Kosugi Y, Kimura I, et al; Genotype to Phenotype Japan (G2P-Japan) Consortium. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. *Lancet Infect Dis*. 2022 Jul;22(7):942-943. doi: 10.1016/S1473-3099(22)00365-6. Epub 2022 Jun 9. PMID: 35690075; PMCID: PMC9179126.

Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. *Nature*. 2022 Jun 17. Doi: 10.1038/s41586-022-04980-y. Epub ahead of print. PMID: 35714668.

Takashita E, Yamayoshi S, Simon V, et al. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. *N Engl J Med*. 2022 Aug 4;387(5):468-470. Doi: 10.1056/NEJMc2207519. Epub 2022 Jul 20. PMID: 35857646; PMCID: PMC9342381.

### **Treatments that are *not* recommended for COVID-19 at this time**

#### **Convalescent Plasma**

Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *JAMA* 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044. Erratum in: *JAMA* 2020 Aug 4;324(5):519. PMID:32492084; PMCID: PMC7270883.

Simonovich VA, Burgos Prax LD, Scibona P, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. *N Engl J Med* 2021 Feb 18;384(7):619-629. doi: 10.1056/NEJMoa2031304. Epub 2020 Nov 24. PMID: 33232588; PMCID: PMC7722692.

Agarwal A, Mukherjee A, Kumar G, et al; PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). *BMJ*. 2020 Oct 22;371:m3939. doi: 10.1136/bmj.m3939. Erratum in: *BMJ*. 2020 Nov 3;371:m4232. PMID: 33093056; PMCID: PMC7578662.

Libster R, Pérez Marc G, Wappner D et al; Fundación INFANT–COVID-19 Group. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *N Engl J Med*. 2021 Feb 18;384(7):610-618. doi: 10.1056/NEJMoa2033700. Epub 2021 Jan 6. PMID: 33406353; PMCID: PMC7793608.

Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. *N Engl J Med*. 2021 Mar 18;384(11):1015-1027. doi: 10.1056/NEJMoa2031893. Epub 2021 Jan 13. PMID: 33523609; PMCID: PMC7821984.

Joyner MJ, Bruno KA, Klassen SA, et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. *Mayo Clin Proc*. 2020 Sep;95(9):1888-1897. doi: 10.1016/j.mayocp.2020.06.028. Epub 2020 Jul 19. PMID: 32861333; PMCID: PMC7368917.

Korley F.K., Durkalski-Mauldin V., Yeatts S.D. et al. Early Convalescent Plasma for High-Risk Outpatients with COVID-19. *N Engl J Med*. 2021 Aug 18;385:1951-60. DOI: 10.1056/NEJMoa2103784. PMID: 34407339; PMCID: PMC8385553.

Sullivan D.J., Gebo K.A., Shoham E.M., et al. Early outpatient treatment for COVID-19 with convalescent plasma. *N Engl J Med*. 2022 Mar, DOI: 10.1056/NEJMoa2119657. PMID: 35353960.

#### **Interferons**

Hung IF, Lung KC, Tso E, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet* 2020 May 30;395(10238):1695-1704.

Davoudi-Monfared E, Rahmani H, Khalili H, et al. A Randomized Clinical Trial of the Efficacy and Safety of Interferon  $\beta$ -1a in Treatment of Severe COVID-19. *Antimicrob Agents Chemother*. 2020 Aug 20;64(9):e01061-20. doi: 10.1128/AAC.01061-20. PMID: 32661006; PMCID: PMC7449227.

WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 2021 Feb 11;384(6):497-511.

Kalil AC, Mehta AK, Patterson TF et al; ACTT-3 study group members. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Respir Med*. 2021 Dec;9(12):1365-1376. doi: 10.1016/S2213-2600(21)00384-2. Epub 2021 Oct 18. PMID: 34672949; PMCID: PMC8523116.

#### **Fluvoxamine**

Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al; TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. *Lancet Glob Health*. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28. Erratum in: *Lancet Glob Health*. 2022 Feb 24;: PMID: 34717820; PMCID: PMC8550952.

Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19. *N Engl J Med* 2022;387:599-610.

#### **Inhaled budesonide**

Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. *Lancet Respir Med*. 2021 Jul;9(7):763-772. Doi: 10.1016/S2213-2600(21)00160-0. Epub 2021 Apr 9. Erratum in: *Lancet Respir Med*. 2021 Jun;9(6):e55. PMID: 33844996; PMCID: PMC8040526.

Yu LM, Bafadhel M, Dorward J, et al; PRINCIPLE Trial Collaborative Group. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *Lancet*. 2021 Sep 4;398(10303):843-855. Doi: 10.1016/S0140-6736(21)01744-X. Epub 2021 Aug 10. Erratum in: *Lancet*. 2021 Aug 18; PMID: 34388395; PMCID: PMC8354567.

#### **Lopinavir/ritonavir**

Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir/ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med*. 2020;382(19):1787-1799. Doi:10.1056/NEJMoa2001282.

WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. *N Engl J Med*. 2021 Feb 11;384(6):497-511.

#### **Ivermectin**

López-Medina E, López P, Hurtado IC, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. *JAMA*. 2021 Apr 13;325(14):1426-1435. Doi: 10.1001/jama.2021.3071. PMID: 33662102; PMCID: PMC7934083.

Lim SCL, Hor CP, Tay KH, et al. Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities. *JAMA Intern Med* 2022; :1–10.

Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19. *N Engl J Med* 2022;387:599-610.

#### **Hydroxychloroquine**

RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med*. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8. PMID: 33031652; PMCID: PMC7556338.

WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 2021 Feb 11;384(6):497-511.

### **Box 2. Key changes since last interim guidance (version 9 dated 28 April 2022 and version 10.1 dated 29 Aug 2022)**

#### **Version 10**

- Dosage of tixagevimab/cilgavimab increased to 600 mg for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP)
- Updates on the use of sotrovimab and casirivimab/imdevimab with current circulating Omicron variants
- Statement on viral rebound with antivirals
- Corrigendum from v9.0 re: molnupiravir to be used for only  $\geq 18$  years of age


## 2. Clinical severity of COVID-19

COVID-19 severity	
Asymptomatic or Presymptomatic	Test positive for SARS-CoV-2 with a virologic test but have no symptoms consistent with COVID-19
Mild	Any signs/symptoms of COVID-19 (e.g. fever, cough, sore throat, malaise, headache, myalgia, nausea, vomiting, diarrhoea, loss of taste/smell) but who do not have shortness of breath or clinical signs of pneumonia or abnormal chest imaging
Moderate	Shows evidence of lower respiratory tract disease during clinical assessment or imaging and who have a SpO <sub>2</sub> of $\geq 94\%$ on room air.
Severe	Individuals who have a SpO <sub>2</sub> of $<94\%$ on room air, or P/F ratio of $<300$ mmHg, respiratory rate of $>30$ breaths/minute or lung infiltrates occupying $>50\%$ of lung fields
Critical	Individuals with respiratory failure, septic shock, and/or multiple organ dysfunction

\*COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed [15 Dec 2020].

## 3. Staging for COVID-19

The staging proposed by Siddiqi et al is a conceptual framework for patients with COVID-19, however bear in mind individual patient's courses may vary and not all patients enter Stage II or III.



Framework proposed by Siddiqi et al, "COVID-19 Illness in Native and Immunosuppressed States", J Heart and Lung Transplantation, 2020.

## 4. Therapeutic Recommendations for COVID-19


### I) Level of Recommendations

The level of recommendations are adapted from the Oxford Centre for Evidence-Based Medicine.

Category	Definition
Levels of evidence	
I	Systematic reviews, meta-analyses, well-designed randomized controlled trials (Phase 3)
II	Two groups, non-randomized studies (e.g. cohort, case-control) or early phase (e.g. Phase 2, or which lack sufficient power) or Phase 3 randomized controlled trials which may be limited by generalisability or biases
III	One-group, non-randomized studies (e.g. before and after, pre-test and post-test)
IV	Descriptive studies that include analysis of outcomes (single-subject design, case series), randomized controlled trials which are not peer reviewed
V	Case reports and expert opinion that include narrative literature, reviews and consensus statements
Grades of evidence	
A	Consistent level I studies
B	Consistent level II or III studies or extrapolations from level I studies or pending replication of results from further level I studies
C	Level IV studies or extrapolations from level II or III studies
D	Level V evidence or troublingly inconsistent or inconclusive studies at any level
Strength of recommendations*	
Strong	Evidence from studies at low risk of bias
Moderate	Evidence from studies at moderate risk of bias
Weak	Evidence from studies at high risk of bias

\* Recommendations may also be labelled as “conditional”, where the workgroup considers that there are sufficient evidence for desirable effect of adherence to a recommendation probably outweigh the undesirable effects, but is not confident about these trade-off, or full peer-review of data is awaited.

## II) Treatment Algorithm for COVID-19



<sup>^</sup> Use monoclonals for which activity is predicted for the variant the patient is infected with \*Or equivalent steroid. All patients: Risk stratify risk for venous thromboembolism with the PADUA score and risk for bleeding VTE bleeding risk score. Patients with severe COVID-19 or a PADUA score  $\geq 4$ , and without contraindications should be started on pharmacologic thromboprophylaxis, till discharge from acute or community care facility. If there are contraindications to pharmacologic thromboprophylaxis, mechanical thromboprophylaxis should be considered (e.g. pneumatic calf pumps)

## III) Recommendations

### RECOMMENDED THERAPEUTIC MANAGEMENT BASED ON DISEASE SEVERITY

#### ***Mild to moderate illness (not requiring supplemental oxygen)***

- i. Most patients with COVID-19 **do not** require specific antiviral treatment, beyond supportive care.
- ii. Clinicians may consider using tools such as the ISARIC 4C Mortality Score for COVID-19 (<https://www.mdcalc.com/4c-mortality-score-covid-19>) to risk stratify patients.
- iii. For selected patients who are at high risk of disease progression, we recommend either
  - a. Oral antivirals (e.g. nirmatrelvir/ritonavir or molnupiravir)
  - b. Remdesivir
  - c. Monoclonal antibodies (which have activity against circulating variants)

#### **RATIONALE FOR ORAL ANTIVIRALS**

(Level 1, Grade B, Moderate, nirmatrelvir/ritonavir, Level 1, Grade B, Low, molnupiravir)

Two oral antivirals are available in Singapore – molnupiravir and nirmatrelvir/ritonavir (Paxlovid). Nirmatrelvir/ritonavir was granted interim authorisation by HSA on 3 February 2022, and molnupiravir on 19 April 2022, via the Pandemic Special Access Route (PSAR).

- Molnupiravir: In the phase 3 MOVE-OUT trial comprising a total of 1433 subjects, 716 were assigned to receive molnupiravir and 717 to receive placebo.[1] Participants had symptomatic COVID-19 with onset within 5 days and laboratory-confirmed disease, and at least 1 risk factor for severe disease. The percentage of participants who were hospitalized or died through day 29 was lower in the molnupiravir group than in the placebo group (6.8% [48 of 709] vs. 9.7% [68 of 699]; difference, -3.0 percentage points; 95% confidence interval, -5.9 to -0.1). The rate of hospitalization or death through day 29 was approximately 31% lower with molnupiravir than with placebo (hazard ratio, 0.69; 95% CI, 0.48 to 1.01). This trial enrolled laboratory-confirmed COVID-19 patients who had not been vaccinated against SARS-CoV-2 and had symptom onset within 5 days.
- Nirmatrelvir/ritonavir (Paxlovid): The Phase 2/3 EPIC-HR study was a randomized, double-blind 1:1 study of non-hospitalized adult patients with COVID-19, who were deemed to be at high risk of progressing to severe illness.[2] Subjects were  $\geq 18$  years with at least 1 risk factor for progression to severe disease. Subjects with COVID-19 symptom onset of  $\leq 5$  days were included in the study, and excluded individuals with a history of prior COVID-19 infection or vaccination. The primary efficacy endpoint was the proportion of subjects with COVID-19 related hospitalization or death from any cause through Day 28. The scheduled interim analysis showed an 89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset (primary endpoint); 0.8% of patients who received nirmatrelvir/ritonavir were hospitalized through Day 28 following randomization (3/389 hospitalized with no deaths), compared to 7.0% of patients who received placebo and were hospitalized or died (27/385 hospitalized with 7 subsequent deaths)( $p < 0.0001$ ). For those treated within five days of symptom onset; 1.0% of patients who received nirmatrelvir/ritonavir were hospitalized through Day 28 following randomization (6/607 hospitalized, with no deaths), compared to 6.7% of patients who received a placebo (41/612 hospitalized with 10 subsequent deaths) ( $p < 0.0001$ ). In the overall study population through Day 28, no deaths were reported in patients who received nirmatrelvir/ritonavir as compared to 10 (1.6%) deaths in patients who received placebo. Real world observational data from Israel in a overall study population with 78% with previous immunity to SARS-CoV-2 (induced by vaccination, infection or both) has also found that hospitalization and death due to COVID-19 were significantly lower in older adults ( $\geq 65$  years) for those who received nirmatrelvir/ritonavir versus those who did not (adjusted hazard ratio, aHR 0.27 95 CI 0.15-0.49), with no evidence of such benefit in younger adults.[3]

Based on the above trials, the oral antivirals **may** be considered for patients for whom there is concern for progressive disease who are within 5 days of symptom onset, **AND** who have lab confirmed COVID (positive PCR /nucleic acid amplification test (NAAT), or a positive antigen test) who have one or more risk factors for progression to severe disease (Annex C).

Risk factors for severe disease include:

- age  $\geq 60$  years (if not fully vaccinated),  $\geq 70$  years (if fully vaccinated)

- active cancer,
- chronic kidney disease,
- chronic obstructive pulmonary disease,
- obesity,
- heart conditions (e.g. heart failure, coronary artery disease (CAD), and/or cardiomyopathies),
- poorly controlled diabetes mellitus (DM) or DM with end-organ involvement (macrovascular – e.g. stroke/coronary artery disease or microvascular disease – nephropathy, retinopathy, neuropathy),
- immunosuppressive disease/treatment.

Eligible patients with clinical or radiographic evidence (if imaging is available) of pneumonia and/or an elevated CRP (>50 mg/L)(if laboratory testing is available) should be prioritised for treatment.

It should be noted that fully vaccinated and boosted patients (i.e. up-to-date on COVID-19 vaccines) are generally at much lower risk of severe COVID-19 - if clinically well, and deemed to be at low risk of progression (e.g. normal vitals/saturation/physical examination and up-to-date on COVID-19 vaccinations), careful observation without specific COVID-19 treatment, with reassessment as necessary, may be reasonable.

If treatment with oral antivirals are indicated, and being considered, we recommend prioritising nirmatrelvir/ritonavir over molnupiravir, given the greater relative risk reduction anticipated in severe outcomes / mortality, although there are no head-to-head trials. Molnupiravir may be considered when there are contraindications to nirmatrelvir/ritonavir (e.g. due to drug-drug interactions, a GFR of <30 ml/min or severe hepatic impairment [Child-Pugh Score C]).

#### ***Cautions with molnupiravir***

Molnupiravir is not authorized for use in patients younger than 18 years of age because it may affect bone and cartilage growth, and because of theoretical concerns of mutagenesis, should not be prescribed to pregnant women or those who are breast feeding. **Females** of childbearing potential should use a reliable method of contraception correctly and consistently, as applicable, for the duration of treatment and for **four days after the last dose of molnupiravir**. **Males** of reproductive potential who are sexually active with females of childbearing potential should use a reliable method of contraception correctly and consistently during treatment and **for at least three months after the last dose**.

#### ***Cautions with nirmatrelvir/ritonavir (Paxlovid)***

Nirmatrelvir/ritonavir (Paxlovid) is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults (18 years of age and older weighing at least 40 kg). Nirmatrelvir/ritonavir (Paxlovid) is a potent CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving Nirmatrelvir/ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. Initiation of medications that inhibit or induce CYP3A may increase or decrease

concentrations of nirmatrelvir/ritonavir (Paxlovid), respectively. **Serious and/or life-threatening reactions may occur due to these interactions**, and prescribers should carefully evaluate for such concomitant drug interactions when prescribing nirmatrelvir/ritonavir (Paxlovid). In patients on chronic medications which may interact with nirmatrelvir/ritonavir, a pharmacist and/or a drug database should be consulted, and clinicians should consider consultation with the patient's primary doctor managing their chronic medical condition and/or Infectious Diseases, if any doubt.

Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions:

- Alpha1-adrenoreceptor antagonist: alfuzosin
- Analgesics: pethidine, piroxicam, propoxyphene
- Antianginal: ranolazine
- Antiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidine
- Anticoagulants: rivaroxaban
- Anti-gout: colchicine
- Antipsychotics: lurasidone, pimozide, clozapine
- Ergot derivatives: dihydroergotamine, ergotamine, methylergonovine
- HMG-CoA reductase inhibitors: lovastatin, simvastatin
- Immunosuppressants: cyclosporine, tacrolimus, sirolimus
- PDE5 inhibitor: sildenafil (Revatio®) when used for pulmonary arterial hypertension (PAH)
- Sedative/hypnotics: triazolam, oral midazolam

(Note : Nirmatrelvir/ritonavir may decrease the levels of warfarin leading to a subtherapeutic INR due to ritonavir-related induction of CYP2C9)

Nirmatrelvir/ritonavir cannot be started immediately after discontinuation of any of the following medications due to the delayed offset of the recently discontinued CYP3A inducer:

- Anticancer drugs: apalutamide
- Anticonvulsant: carbamazepine, phenobarbital, phenytoin
- Antimycobacterials: rifampin
- Herbal products: St. John's Wort (*Hypericum perforatum*)

The above interactions are **not exhaustive**. Clinicians are advised to review drug interactions with a drug reference or interaction checker (e.g. <https://www.covid19-druginteractions.org> by the Liverpool Drug Interaction Group), and consult a pharmacist if needed. Common drug-drug interactions and possible actions are listed in Annex D. Management of drug interactions may be complex, and options may include using an alternate COVID-19 therapeutic, temporarily pausing or dose-adjusting concurrent medications (for a further 3 days **after** the completion of the 5-day course of nirmatrelvir/ritonavir, i.e. a total of 8 days)

### ***Viral rebound***

A phenomenon known as “viral rebound” has been described, where patients may report developing acute respiratory infection symptoms associated with COVID-19 again, and antigen

tests may become positive again. This has been described in 0.8% - 8% of patients treated with paxlovid or molnupiravir [4,5], and also up to 12% of patients without COVID-19 specific treatment. [6] In one study looking at rebound in those treated with paxlovid these were generally mild, occurred at a median of 9 days after treatment, and all resolved without any further COVID-19 directed therapy. [5] As these are usually mild and follow a benign course and re-treatment with OAVs is not typically recommended. In terms of the isolation period for patients with “viral rebound”, patients may need to be clinically reviewed and be provided with an extension if still symptomatic, as per the initial assessment of patients with COVID-19, using MOH protocol 1-2-3.

#### **RATIONALE FOR REMDESIVIR (Level II, Grade B, Moderate)**

The phase 3 PINETREE study consisting of 562 high risk patients (aged  $\geq 12$  years with risk factors or  $\geq 60$  years) with confirmed COVID-19 (within 4 days of diagnosis, symptoms for  $\leq 7$  days) who were not hospitalised were randomised 1:1 to receive 3 days of remdesivir or placebo, found a 87% reduction in the risk of a composite of COVID-19 related hospitalisation or all-cause death with remdesivir vs placebo [0.7% vs 5.3%;  $p=0.008$ ] at day 28. The risk of COVID-19-related medically attended visits or all-cause death by day 28 was also reduced by 81% with remdesivir compared with placebo (1.6% vs 8.3%;  $p=0.002$ ). [7] It should be noted there were no deaths in either arm of the PINETREE trial and only unvaccinated subjects were included. The trial was also conducted prior to the emergence of the Delta and Omicron variants.

Prior to the PINETREE study, an open-label randomised controlled trial in patients with moderate COVID-19 pneumonia (i.e. not on oxygen at enrolment) found a better clinical status distribution in persons randomised to a 5 day course of remdesivir than those who received standard of care and suggested a modest clinical benefit, but did not have a statistically significant difference in clinical status compared with standard care at 11 days after initiation of treatment. [8]

#### **RATIONALE FOR MONOCLONAL ANTIBODIES (MAbs)**

(sotrovimab; tixagevimab-cilgavimab, ungraded)

Three monoclonal antibody therapies – tixagevimab-cilgavimab (Evusheld), sotrovimab and casirivimab/imdevimab (REGEN-COV) – are available in Singapore for the management of COVID-19, although casirivimab/imdevimab is now not currently in use as due to suboptimal activity against the circulating Omicron subvariants. Casirivimab/imdevimab and sotrovimab were approved by HSA via the PSAR (pandemic special access route) and also received US FDA emergency use authorisation (EUA) for the treatment of mild-moderate COVID-19 in adults weighing at least 40kg who are at high risk for progression to severe disease. Tixagevimab-cilgavimab was approved by HSA via PSAR and the US FDA for **pre-exposure prophylaxis** for COVID-19, and although in a recent trial (TACKLE) it showed positive results for treatment of mild-moderate COVID-19 [9], it has not received HSA or US FDA approvals for treatment as of the issuance date of these guidelines.

While there are no head-to-head comparative data to determine whether there are differences in clinical efficacy or safety between these therapies, certain SARS-CoV-2 variants are predicted to reduce the virus’ susceptibility to these monoclonal antibodies in vitro. In vitro-data suggest

that tixagevimab-cilgavimab retains at least some activity against BA.2 and BA.4/5. Sotrovimab retains at least some activity against Omicron variants BA.1 and BA.1.1, but has poorer in vitro neutralization for BA.2 and BA.4/5. Casirivimab/imdevimab does not have activity against BA.1 and while imdevimab has some in-vitro activity against BA.2, BA.4/5, data has been inconsistent in different studies [10–12](See Annex A, Tables 1-4).

Administration of tixagevimab-cilgavimab and sotrovimab to individuals at high risk for disease progression in early illness has been tested in phase 3 clinical trials:

- Tixagevimab-cilgavimab (Evusheld): In October 2021, AstraZeneca announced positive results from the tixagevimab-cilgavimab TACKLE Phase III outpatient treatment trial. TACKLE is a Phase III, randomised, double-blind, placebo-controlled, multi-centre trial assessing the safety and efficacy of a single 600mg IM dose of tixagevimab-cilgavimab compared to placebo for the outpatient treatment of COVID-19. Tixagevimab/cilgavimab reduced the risk of developing severe COVID-19 or death (from any cause) by 50% compared to placebo in outpatients who had been symptomatic for 7 days or less, with 18 events in tixagevimab/cilgavimab arm (18/407) and 37 in the placebo arm (37/415). In a prespecified analysis of participants who received treatment within five days of symptom onset, tixagevimab/cilgavimab reduced the risk of developing severe COVID-19 of death (from any cause) by 67% compared to placebo, with nine events in the tixagevimab/cilgavimab arm (9/253) and 27 in the placebo arm (27/251). [9]
- Sotrovimab: The Phase 3 COMET-ICE trial, a randomised, double-blind, placebo-controlled study that evaluated sotrovimab as monotherapy for the early treatment of COVID-19 ( $\leq 5$  days after the onset of symptoms) in adults at high risk of hospitalisation, has reported interim[13] and final results.[14] The study endpoint was assessed on day 29 post-treatment. Based on the interim analysis from 583 patients, there was an 85% reduction in the relative risk for progression to hospitalisation for acute treatment (of >24 hours) or death compared to placebo, with a relative risk ratio (RRR) of 0.15 ( $p = 0.002$ ). The final analysis when all 1,057 subjects were included, demonstrated a 79% relative risk reduction, RRR = 0.21 ( $p < 0.001$ ). There were 6% (30 / 529) of subjects in the placebo group and 1% (6 / 528) in the sotrovimab group who had progressed. There were lower proportions of subjects in the sotrovimab group (1%) compared to the placebo group (5%) who progressed to severe or critical respiratory disease requiring oxygen supplementation. The mortality rates due to COVID-19 were very low, with no death reported in the sotrovimab group and 2 deaths (<1%) in the placebo group. With the emergence of the Omicron BA.2 variant, the neutralizing activity of sotrovimab was found to be diminished in in vitro studies and an increased dosage of 1000 mg has been recommended by the manufacturer based on safety and modelled pharmacodynamics/kinetic data[15,16] . The COMET-TAIL trial studied 500 mg of intravenous versus intramuscular sotrovimab administered within 7 days of onset of symptoms and found that the intramuscular route was non-inferior to the intravenous route, full published results are pending .[17] The RECOVERY trial is studying the 1000 mg dose in hospitalized patients with COVID-19. The published safety data of sotrovimab do not suggest safety concerns at this higher dose.[18] One smaller Singapore study during

the Delta wave found that sotrovimab was protective against, and diminished significantly time to clinical deterioration.[19] Further real-world clinical data is needed to confirm the efficacy of therapy with sotrovimab and tixagevimab/cilgavimab against Omicron subvariants.

On 11 February 2022, another monoclonal with in-vitro Omicron activity, bebtelovimab was authorized for emergency use by the FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and paediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, at high risk for progression to severe COVID-19, for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.[20,21] Bebtelovimab is not currently available in Singapore.

Based on the published or released data, and during the current period when Omicron BA.4/5 subvariants are predominant, tixagevimab-cilgavimab may be considered in:

- high risk patients with laboratory confirmed COVID-19 AND
- Who are within 7 days of symptom onset

If tixagevimab/cilgavimab is not available or unsuitable, sotrovimab *may* be considered if Mab therapy is being considered. We do not recommend the use of casirivimab/imdevimab given the current circulating Omicron subvariants.

This recommendation may be reviewed periodically depending on circulating VOCs and their susceptibility to the MABs. The trials supporting the use of the monoclonals were performed prior to the emergence of the Omicron variant. **Physicians should use a MAB which is predicted to have activity, depending on the predominant circulating variant where the infection was acquired or if the variant the patient is infected with is known (e.g. via variant typing).** Priority should be given to those who are unvaccinated for COVID-19, or who are seronegative/have a waned antibody response for SARS-CoV-2.

*While tixagevimab-cilgavimab has received PSAR authorisation for **pre-exposure prophylaxis** for COVID-19, it has not received PSAR authorisation for treatment of COVID-19, as of the issuance date of this guidance. Based on available evidence, tixagevimab-cilgavimab may be considered for treatment, although it is considered 'off-label', and requesting doctors are fully responsible for the use of tixagevimab-cilgavimab on patients. Risk, benefits and potential adverse events (RBAE) should be discussed with patients and documented.*

Useful sites to refer to for the activity of the various monoclonals and antivirals against specific SARS-CoV-2 variants:

- 1) NIH COVID-19 Therapeutic Activity Explorer: <https://opendata.ncats.nih.gov/variant/activity>
- 2) Stanford University Coronavirus Antiviral & Resistance Database: <https://covdb.stanford.edu/page/susceptibility-data/>

The ISARIC 4C Severity or Mortality scores may be used to risk stratify patients. High risk patients (e.g. ISARIC 4C Mortality score  $\geq 7$ ), in particular those who are not up-to-date with COVID-19 vaccination/not fully vaccinated, may be considered for monoclonal antibody therapy . On a case-

by-case basis and as guided by Infectious Disease consultation and/or the institution's stewardship team the MABs (or remdesivir) may be considered for those who at the point of assessment might be at lower risk of mortality (e.g. ISARIC 4C mortality score <7), but nonetheless are deemed to be at high risk for severe disease e.g. for those who are immunocompromised (e.g. by EC19V criterion, see Annex B) and/or who are not expected to have a good response to COVID-19 vaccination. When considering MABs in these instances clinicians may consider corroboration with a serologic assay (e.g. Anti S antibody or neutralising antibody levels), prior to administration of monoclonals. There is, as yet, no generally defined Anti-S antibody titre that correlates with protection from severe COVID-19. In terms of expected vaccine responses post mRNA vaccination, one study in a patient population with chronic lymphocytic leukaemia (CLL) and a poor response to vaccine found Anti-S levels on the Roche Elecys platform to be 53 U/mL in vaccinees with CLL vs 3900 U/mL in healthy subjects, 2-3 weeks after vaccination with the Pfizer BNT162b2 mRNA vaccine.[22] With a surrogate virus neutralisation test (Cpass®, GenScript) a result of inhibition <30% indicates a sample which is negative for neutralizing antibodies, per the manufacturer.[23] In seropositive patients at high-risk of progression, with good anti-S or neutralizing antibody levels and mild-moderate COVID-19, clinicians may consider antivirals (e.g. remdesivir or the oral antivirals), if indicated.

Hospitals should track the use of SARS-CoV-2 monoclonal antibodies as part of a hospital-based monitoring programme. Healthcare providers should consult the latest Ministry of Health (MOH) guidance on reporting requirements.

### ***Severe illness (requiring supplemental oxygen but not invasive ventilation or ECMO)***

For patients with severe illness requiring supplemental oxygen but not invasive ventilation or ECMO, we recommend either

- i. Dexamethasone (or equivalent steroid)
- ii. Dexamethasone (or equivalent steroid) + Remdesivir
- iii. Remdesivir + Baricitinib
- iv. Dexamethasone (or equivalent steroid) + Baricitinib
- v. Dexamethasone (or equivalent steroid) + Remdesivir + Baricitinib

#### **RATIONALE FOR DEXAMETHASONE (Level I, Grade A, Strong)**

Prior to results released by the RECOVERY trial, steroids were not conclusively shown to have specific benefits in COVID-19 infection, and the evidence had been somewhat conflicting.[24] Studies with reported benefits have been uncontrolled, and confounded by concurrent treatments, and steroids have been known to cause deleterious effects (e.g. bacterial/fungal superinfection) from SARS (2003) data. Steroid bursts ( $\leq 14$  days) have also been found to be associated with a significant increase in incidence of gastrointestinal bleeding, sepsis, and heart failure within the first month after initiation of steroid therapy.[25]

The RECOVERY trial results reported on 2104 patients who were randomised (unblinded) to received dexamethasone and 4321 patients to standard of care.[26] It should be noted that <0.1% of patients in the RECOVERY trial received concomitant remdesivir. Patients were eligible if they were hospitalised, and had clinically suspected or laboratory confirmed COVID-19. Dexamethasone was given orally or intravenous at a dose of 6mg once daily for up to 10 days (or until hospital discharge if

sooner) (median duration, 7 days). The trial found that significantly lower mortality in patients allocated to dexamethasone (overall 22.9% vs 25.7%,  $p < 0.001$ ; if on mechanical ventilation 29.3% vs 41.4%, 95% CI 0.51 to 0.81); if receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; 95% CI 0.72 to 0.94). There was no statistically significant benefit if patients were not receiving any respiratory support (17.8% vs. 14.0%, 95% CI 0.91 to 1.55).

A randomised controlled trial (RCT) (n=86 hospitalised patients) which compared methylprednisolone (2 mg/kg/day; intervention group) versus dexamethasone (6 mg/ day; control group) found that methylprednisolone demonstrated significantly better clinical status compared to the control group at day 5 (4.02 vs. 5.21,  $p = 0.002$ ) and day 10 (2.90 vs. 4.71,  $p = 0.001$ ) of admission, a significant difference in the overall mean score (3.909 vs. 4.873,  $p = 0.004$ ), a shorter mean length of hospital stay ( $7.43 \pm 3.64$  vs.  $10.52 \pm 5.47$  days,  $p = 0.015$ ), and a lower need for a ventilator (18.2% vs 38.1%,  $p = 0.040$ ).[27] Further studies are needed to assess the comparative performance and optimal dosing of various steroid preparations.

A prospective meta-analysis of 7 randomised trials (DEXA-COVID 19, CoDEX, RECOVERY, CAPE COVID, COVID STEROID, REMAP-CAP, Steroids-SARI) consisting of 1703 patients had also found that treatment with corticosteroids (dexamethasone, hydrocortisone, methylprednisolone) was associated with a lower 28-day all-cause mortality for critically ill patients with COVID-19, compared with usual care or placebo. There were 222 deaths among 678 patients randomised to corticosteroids, and 425 deaths among 1025 patients randomised to usual care or placebo (summary OR 0.66; 95% CI: 0.53 to 0.82;  $P < 0.001$ ).[28]

The COVID STEROID 2 Trial Group randomized adults with confirmed COVID-19 requiring at least 10L/min of oxygen or mechanical ventilation comparing intravenous dexamethasone 12mg/day vs. 6mg/day for up to 10 days. The median number of days alive without life support (22.0 days vs 20.5 days;  $p=0.07$ ) and mortality at 28 days [27.1% vs 32.3%; adjusted relative risk, 0.86 (99% CI 0.68-1.08)] was not significantly different between the groups.[29] The HIGHLOWDEXA trial was a randomized, controlled clinical trial evaluating high dose dexamethasone (20 mg once daily for 5 days, followed by 10 mg once daily for 5 days) vs low dose dexamethasone (6 mg once daily for 10 days) in patients hospitalized with COVID-19 pneumonia requiring oxygen therapy.[30] They found that while that 31.4% of patients in the low dose group and 16.3% of those in the high dose group exhibited clinical worsening within 11 days of randomization (rate ratio, 0.427; 95% CI, 0.216-0.842;  $P = .014$ ), there was no significant difference in the 28-day mortality (5.9% in the low dose group and 6.1% in the high dose group,  $P = 0.844$ ), time to recovery or in the 7-point ordinal scale at day 5, 11, 14 and 28. The results in this trial were confounded because 32 (31.4%) of the 102 patients in the low dose dexamethasone group subsequently received high dose dexamethasone due to clinical worsening, which was allowed per the clinical protocol, and this potentially biased results.

Additional trials are underway (NCT04381936, NCT04663555) to clarify optimal steroid dosing.

Given the above findings, oral or intravenous dexamethasone 6 mg daily (equivalent to oral prednisolone 40 mg daily, intravenous methylprednisolone 32 mg daily or intravenous hydrocortisone 50mg q8 hours) for up to 10 days is recommended in patients with severe COVID-19 requiring supplemental oxygen or mechanical ventilation and who do not have contraindications to such treatment.

**RATIONALE FOR DEXAMETHASONE + REMDESIVIR (Level 2, Grade B, Weak)**

One large RCT, ACTT-1, on 1062 patients (541 remdesivir, 521 placebo) showed a shortened time to recovery in hospitalised patients with COVID-19 (10 days vs 15 days,  $P < 0.001$ ) based on an eight-point ordinal scale, although no significant mortality difference was noted (6.7% with remdesivir and 11.9% with placebo by day 15, and 11.4% with remdesivir and 15.2% with placebo by day 29; hazard ratio 0.73; 95% CI 0.52 to 1.03;  $p = 0.07$ ).<sup>[31]</sup> Specifically, the largest difference observed in HR for mortality was 0.30 (95% CI 0.14-0.64) for patients in category 5 (hospitalized, requiring any supplemental oxygen, but not non-invasive or invasive ventilation, or ECMO). In this study, remdesivir was more effective when given to patients who were not as severely ill, and in subgroup analyses the time to recovery was significant for the group on supplemental oxygen (but not for those with more severe disease on ECMO, invasive mechanical ventilation or high flow nasal oxygen), or milder disease (not on oxygen).<sup>[31]</sup> The benefit of remdesivir for reducing time to recovery was most evident in the subgroup of patients who required supplemental oxygen (baseline ordinal score of 5; recovery rate ratio 1.45 (95% CI 1.18 to 1.79). This is hypothesized to be related to the mechanism of action of remdesivir as an antiviral which is usually best given during the viral replicative phase in early illness in COVID-19, prior to clinical worsening (e.g. need for mechanical ventilation). ACTT-1 also showed that remdesivir reduced progression to high flow oxygen or non-invasive ventilation, or progression to mechanical ventilation.

Another study did not find a difference in clinical improvement between a 5-day vs 10-day course of remdesivir for hospitalised patients with COVID-19, <sup>[32]</sup> although this study was limited in terms of not having a control group, and was thus unable to measure the magnitude of benefit. It should be noted that those receiving mechanical ventilation and extracorporeal membrane oxygenation (ECMO) at screening were excluded, as were those who had signs of multi-organ failure.

A third study with 237 patients in COVID-19 in China did not find a statistically significant different time to clinical improvement, although this trial was felt to be underpowered as it was terminated earlier due to improvement in the COVID-19 situation in Hubei, China and inability to recruit further.<sup>[33]</sup>

A randomised open-label adaptive trial sponsored by the World Health Organisation evaluating remdesivir, hydroxychloroquine, lopinavir/ritonavir, interferon-beta versus standard of care (SOLIDARITY trial) consisting of a total of 11,266 patients.<sup>[34]</sup> There were 2,750 patients allocated to the remdesivir group and 2708 patients to standard of care. Overall in-hospital mortality was similar between remdesivir and standard of care (11% vs 11.2%; rate ratio 0.95; 95% CI 0.81 to 1.11;  $p = 0.50$ ). In the subgroup analysis, in-hospital mortality among patients on supplemental oxygen at enrollment was 12.2% in the remdesivir group compared to 13.8% in the standard of care arm (rate ratio 0.86; 95% CI 0.67 to 1.11), while the mortality among patients ventilated at enrollment was 43.0% versus 37.8% (rate ratio 1.2; 95% CI 0.80 to 1.80).<sup>[34]</sup>

Methodological differences between SOLIDARITY and ACTT-1 should be noted,<sup>[35]</sup> despite both being RCTs, including study size and different primary end-points, and the former being a pragmatic open label trial (remdesivir versus standard of care) whereas the latter a placebo-controlled double blinded trial.

The Health Sciences Authority (HSA) conditionally approved remdesivir for treatment of COVID-19 in Singapore on 10 June 2020, for adult patients with  $SpO_2 \leq 94\%$  (room air), or those requiring oxygen supplementation, mechanical ventilation or ECMO, for treatment up to 10 days. Based on the data by

Beigel et al, we recommend an initial treatment duration of 5 days in early, severe COVID-19.[31] This might be extended for up to 10 days in patients with more severe illness. If remdesivir is considered in patients with severe COVID-19, combination therapy should be strongly considered unless there is a contraindication to steroid use. In a very select group of patients with early severe disease on low flow oxygen(i.e.,  $\leq 4\text{L}/\text{min}$ ), remdesivir alone, with close observation, may be a reasonable initial option, with a view of add on steroid treatment if there is worsening. One retrospective study found that remdesivir-only patients (n=985) on low-flow oxygen were also significantly more likely to clinically improve with a median time to improvement of 5 days (IQR, 4,8) compared to 8 days (IQR, 5,19) in controls (aHR 1.66 [95% CI, 1.35-2.04].[36]

Remdesivir plus dexamethasone has not been directly compared to dexamethasone alone in large randomized clinical trials. One retrospective, multicentre study (n=2483) comprising a subset of 184 patients receiving remdesivir plus corticosteroids with 158 patients receiving remdesivir alone found that adding dexamethasone to remdesivir compared to remdesivir alone did not show a significant reduction in the hazard of death for patients who received remdesivir and corticosteroids compared with remdesivir alone (aHR, 1.94; 95%CI, 0.67-5.57).[37]

#### **RATIONALE FOR REMDESIVIR + BARICITINIB (Level I, Grade B, Moderate)**

Baricitinib is an oral JAK inhibitor used in the treatment of rheumatoid arthritis. Its antiviral activity lies in its affinity for adaptor-associated kinase-1 (AAK1) which is a regulator of viral endocytosis, thereby preventing SARS-CoV-2 from entering and infecting pulmonary cells. It also blunts the downstream inflammatory cascade by the inhibition of JAK1/JAK2 kinase and IL-6-induced STAT3 phosphorylation.

On 19 November 2020, the FDA released an Emergency Use Authorisation (EUA) for remdesivir combined with baricitinib. The data supporting this EUA are based on a double-blind, placebo-controlled RCT (ACTT-2) which included 1,033 patients with moderate or severe COVID-19 (515 patients with remdesivir plus baricitinib versus 518 patients with remdesivir plus placebo).[38] The median time to recovery was 7 days for baricitinib plus remdesivir, versus 8 days for remdesivir plus placebo (rate ratio for recovery, 1.16; 95% CI 1.01 to 1.32, p=0.03). Patients who showed the greatest benefit were those with a baseline ordinal score of 6 (i.e. on non-invasive ventilation or high-flow nasal oxygen). These patients had a time to recovery of 10 days in the baricitinib plus remdesivir group versus 18 days in the control group (rate of recovery, 1.51; 95% CI 1.10 to 2.08), and were most likely to have clinical improvement at day 15 (odds ratio 2.2; 95% CI 1.4 to 3.6). The incidence of progression to death or non-invasive ventilation was lower in the combination group than in the control group (22.5% vs 28.4%; rate ratio 0.77, 95% CI 0.60-0.98), as was the incidence of progression to death or invasive ventilation (12.2% vs 17.2%; rate ratio 0.69; 95% CI 0.50 to 0.95). The overall 28-day mortality was 5.1% for the remdesivir plus baricitinib group versus 7.8% for the remdesivir plus placebo group (hazard ratio for death 0.65; 95% CI 0.39 to 1.09).

The ACTT-4 trial (unpublished data) which aimed to examine the efficacy of remdesivir plus baricitinib versus remdesivir plus dexamethasone in preventing progression to intubation or death in patients with severe COVID-19, comprised of 516 subjects in the remdesivir plus baricitinib and 494 subjects in the remdesivir plus dexamethasone arm. The ventilation-free survival was 87.0% in the remdesivir

plus baricitinib group and 87.6% in the remdesivir plus dexamethasone group [risk difference (RD) 0.6%; 95%CI 3.6% to 4.8%; P=0.91]. The clinical status at day 15 was comparable [odds ratio 1.01; 95% CI 0.80 to 1.27]. Adverse events were seen in 29.6% of those treated with remdesivir plus baricitinib group versus 37.1% of those treated with remdesivir plus dexamethasone [RD 7.5%; 95%CI 1.6% to 13.3%; P=0.01], treatment related-adverse events were 4.2% vs. 10.2% [RD 6.0%; 95%CI 2.8% to 9.3%; P=0.0004], and severe or life-threatening adverse events were 28.4% vs. 36.1% [RD 7.7%; 95%CI 1.8% to 13.4%; P=0.01], all respectively higher in the remdesivir plus dexamethasone arm compared to remdesivir plus baricitinib.

#### **RATIONALE FOR DEXAMETHASONE + BARICITINIB (Level I, Grade B, Moderate)**

COV-BARRIER was a phase 3 RCT evaluating baricitinib 4 mg once daily for up to 14 days plus standard of care (n=764) (SoC)(which included 79% receiving corticosteroids and 19% receiving remdesivir, with some receiving both) versus placebo plus SoC (n=761).[39] The trial did not meet statistical significance on the primary endpoint, which was defined as a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation or death by Day 28 (27.8% vs 30.5%; p=0.18). However, the 28-day all-cause mortality was 8.1% for baricitinib and 13.1% for placebo, corresponding to a 38.25% reduction in mortality (hazard ratio 0.57, 95% CI 0.41 to 0.78; nominal p=0.002). A numerical reduction in mortality was observed for all baseline severity subgroups of baricitinib-treated patients and was most pronounced for patients receiving non-invasive mechanical ventilation at baseline (17.5% versus 29.4% for baricitinib plus SoC versus SoC; hazard ratio [HR]: 0.52; 95% CI: 0.33, 0.80; nominal p-value=0.0065).

An RCT (STOP-COVID) comprising 289 patients in Brazil found the decreased cumulative incidence of death or respiratory failure through day 28 with tofacitinib vs placebo (18.1% vs 29%, risk ratio 0.63, 95% CI 0.41-0.97, p = 0.04).[39] The trial included patients 18 years or older with laboratory confirmed COVID-19 infection with pneumonia, who had been hospitalised for <72 hours. Tofacitinib was dosed at 10 mg BD up to 14 days and dose adjusted with renal and hepatic function on those on concurrent medications which were CYP3A4/CYP2C19 inhibitors. Patients on non-invasive or invasive mechanical ventilation and ECMO, and a history of thrombosis or current thrombosis, known immunosuppression, and active cancer on treatment were excluded. In this trial tofacitinib was dosed for a median of 5 days in the intervention group and 89.3% of patients overall received glucocorticoids, and none received remdesivir. Based on these results, and further ongoing trials with tofacitinib, JAK inhibitors may be considered in combination with corticosteroids in patients with severe COVID-19.

#### **RATIONALE FOR DEXAMETHASONE + REMDESIVIR + BARICITINIB (Ungraded)**

Please refer to discussion in the above section under *Severe Illness (requiring supplemental oxygen but not invasive ventilation or ECMO)*—**RATIONALE FOR DEXAMETHASONE + BARICITINIB.**

#### **THE ROLE OF MONOCLONALS IN SEVERE COVID-19**

The benefit of monoclonal antibodies as treatment for moderate to severe COVID-19 has not been demonstrated with the exception of REGEN-COV. [40] **However the applicability of these findings may be limited by the prevailing SARS-CoV-2 variant in circulation, for which the monoclonal in question may not demonstrate sufficient neutralising activity.** For example REGEN-CoV is not active

against the Omicron variant and its use is not recommended at this time. The ACTIV-3 platform trial (NCT04501978) Therapeutics for Inpatients with COVID-19 (TICO) has completed evaluation of four monoclonal antibodies and one monoclonal antibody-like agent (a DARPin). Of these five agents, including sotrovimab, four did not pass an early futility assessment.[41] Tixagevimab/cilgavimab did not show a difference in a primary end-point of sustained recovery compared to placebo, although mortality was lower in with tixagevimab/cilgavimab vs placebo (9% vs 12%) as part of secondary analyses, and this finding requires further validation.[42] Several limitations of the ACTIV-3 trial in assessing the efficacy of tixagevimab/cilgavimab in severe COVID-19 should be noted:

- Enrolment concluded before emergence of the Omicron variant so direct evidence is lacking for patients infected with this or future variants
- Only a minority of participants were fully vaccinated (14-15%), making it difficult to extrapolate results to vaccinated or boosted patients.
- A majority patients received remdesivir (63-64%) and corticosteroids (73%), so the benefit of tixagevimab/cilgavimab if used as antiviral monotherapy is unknown.

### **Critical illness (requiring mechanical ventilation or ECMO)**

For patients with critical illness requiring mechanical ventilation or ECMO, we recommend either

- i. Dexamethasone (or equivalent steroid)
- ii. Dexamethasone (or equivalent steroid) + Tocilizumab
- iii. Dexamethasone (or equivalent steroid) + Baricitinib

#### **RATIONALE FOR DEXAMETHASONE (Level I, Grade A, Strong)**

Please refer to discussion in the above section under *Severe Illness (requiring supplemental oxygen but not invasive ventilation or ECMO)*.

#### **RATIONALE FOR DEXAMETHASONE + TOCILIZUMAB (Level I, Grade B, Moderate)**

Meta-analyses conducted by the WHO Rapid Evidence Appraisal Working Group (REACT)[43] and Cochrane collaboration[44] concluded there was likely to be a mortality benefit with IL-6 antagonists in severe COVID-19 (all-cause mortality at Day 28: OR, 0.86 [95% CI, 0.79-0.95] and RR 0.89, [95 CI 0.82-0.97] respectively).

The two largest clinical trials completed to date (RECOVERY[45] and REMAP-CAP [46]) reported clinical benefits from IL-6 antagonists, however, the next largest trial REMDACTA trial did not.[47] The meta-analysis conducted by REACT included data from all three of these trials:

- RECOVERY is an open-label randomised trial conducted in >4000 patients with oxygen saturation <92% on room air, or oxygen supplementation, and a CRP  $\geq$ 75 mg/L.[45] Study participants were treated with one or two weight adjusted doses of tocilizumab along with standard of care, e.g. steroids (82% receipt). The median CRP at randomisation was 143 (107-203) mg/L. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0.85; 95% CI 0.76–0.94). Consistent results were seen in all pre-specified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be

- discharged from hospital within 28 days (57% vs 50%; rate ratio 1.22; 1.12–1.33). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0.84; 95% CI 0.77–0.92).
- In the REMAP-CAP trial of 804 adult patients critically ill with COVID-19, were randomized within 24 hours after starting organ support in the intensive care unit to receive open-label tocilizumab or sarilumab or usual care alone.[46] Respiratory organ support was defined as invasive or non-invasive mechanical ventilation, including through high-flow nasal cannulae. In this trial, >80% also received concomitant steroids and 33%, remdesivir. The median (IQR) CRP for patients enrolled in the tocilizumab arm was 150 (85-221) mg/L. Compared to usual care, the use of tocilizumab reduced in-hospital mortality (28% vs. 36%) and increased the number of days free of respiratory and cardiovascular organ support (10 days vs. 0 days; OR 1.64; 95% CI, 1.25–2.14)
  - In REMDACTA 434 patients were randomised to tocilizumab plus remdesivir and 215 to placebo plus remdesivir.[47] Overall, 566 patients (88.2%) received corticosteroids during the trial to day 28. Median time from randomization to hospital discharge or “ready for discharge” (study primary endpoint) was 14 (95% CI 12–15) days with tocilizumab plus remdesivir and 14 (95% CI 11–16) days with placebo plus remdesivir; 78 (18.2%) and 42 (19.7%) patients, respectively, died by day 28.

Other individual trials have not shown a consistently beneficial effect of an IL-6 antagonist on clinical outcomes such as mortality or clinical progression (CORIMUNO-TOCI[48], COVACTA[49], EMPACTA[50], Salvarani et al[51], BACC Bay Tocilizumab Trial[52], TOCIBRAS[53], COVINTOC[54]). These studies may have had varied results as they either recruited smaller populations, were heterogenous in their inclusion criterion and importantly, many were conducted before remdesivir and corticosteroids were standard of care.

We recommend a JAK inhibitor or IL-6 antagonist in addition to systemic corticosteroids for selected patients. No data is currently available to determine which should be used in preference. We suggest choosing an IL-6 antagonist for patients with hyperinflammation (e.g. as evidenced by significantly elevated inflammatory markers such as a CRP  $\geq 75$  mg/L and rising) and who are at high risk or are exhibiting rapid respiratory decompensation due to COVID-19. Treating physicians should be aware of the risk of opportunistic infection(s) and lower intestinal perforation, in particular in patients with underlying gastrointestinal disease. Use of IL-6 antagonists should be guided by Infectious Diseases or an intensivist. Consultation with rheumatologists-allergist-immunologists (RAI) may be needed for complex cases. Currently, we do not recommend the use of tocilizumab in patients who are receiving JAK inhibitors (e.g. baricitinib) due to the lack of efficacy and safety data.

#### **RATIONALE FOR DEXAMETHASONE + BARICITINIB (Level II, Grade B, Moderate)**

In an addendum trial to the COV-BARRIER trial, baricitinib was studied in patients on baseline invasive mechanical ventilation/ECMO in a 1:1 randomisation to baricitinib 4-mg (n=51) or placebo (n=50) for up to 14 days in combination with standard of care, which included systemic corticosteroids in 86% of participants.[55] Treatment with baricitinib significantly reduced 28-day all-cause mortality compared to placebo (39.2% vs 58.0%; hazard ratio [HR]=0.54 [95%CI 0.31–0.96]; p=0.030), and also

60-day mortality (45.1% vs 62.0%; HR=0.56 [95%CI 0.33–0.97]; p=0.027). While a large effect size was noted, consistent with results in the main COV-BARRIER trial, this was a small trial. Taken together however, we recommend that baricitinib may be considered in patients on mechanical ventilation or ECMO, and when used, should be in combination with corticosteroids (if there are no contraindications), with or without remdesivir, for the treatment of patients COVID-19 critical illness on mechanical ventilation.

### ***Prophylaxis for COVID-19***

The role of monoclonal antibodies in the prevention (pre- or post-exposure prophylaxis) of COVID-19 are limited: active immunity via an effective SARS-CoV-2 primary vaccine series and boosters as required is clearly preferable. The oral antivirals are not currently indicated for pre- or post-exposure prophylaxis of COVID-19.

#### **PRE-EXPOSURE PROPHYLAXIS**

In December 2021, the U.S. Food and Drug Administration issued an Emergency Use Authorisation (EUA) for the use of Evusheld (tixagevimab co-packaged with cilgavimab) for the pre-exposure prophylaxis (prevention) of COVID-19, based on the PROVENT trial which had met the primary end point of reduction in incidence of symptomatic COVID 19 with tixagevimab-cilgavimab compared to placebo.

PROVENT enrolled adults  $\geq 18$  years of age who were either  $\geq 60$  years of age, had pre-specified co-morbidities (obesity, congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease, immunocompromised state, or previous history of severe or serious adverse event after receiving any approved vaccine), or were at increased risk of SARS-CoV-2 infection due to their living situation or occupation. Subjects could not have previously received a COVID-19 vaccine or have known prior or current SARS-CoV-2 infection. Subjects received a single dose of tixagevimab-cilgavimab (N= 3,441) or placebo (N= 1,731). Receipt of tixagevimab-cilgavimab resulted in a 77% reduction (95% CI: 46, 90) in incidence of SARS-CoV-2 RT-PCR-positive symptomatic illness compared to placebo (p<0.001) in the 5,172 participants who did not have a prior SARS-CoV-2 RT-PCR-positive COVID-19 infection.[56] In a post-hoc analysis (median follow-up 6.5 months), the relative risk reduction of SARS-CoV-2 RT-PCR-positive symptomatic illness was 83% (95% CI: 66 to 91).[57] There were no severe/critical COVID-19 events among subject who received tixagevimab-cilgavimab compared to 5 events among subjects who received placebo.

In PROVENT the dosage of tixagevimab/cilgavimab (Evusheld) PrEP was 150 mg of tixagevimab and 150 mg of cilgavimab and the study was conducted prior to the advent of the Omicron VOC. In light of Omicron and its subvariants, the US FDA increased the authorised dose of Evusheld to 300 mg of tixagevimab and 300 mg of cilgavimab on 24 February 2022, and on 29 June 2022 recommended repeat dosing every six months if continued PrEP is considered based on nonclinical data and pharmacokinetic modelling.[58]

Based on:

- Data indicating diminished neutralizing activity with Omicron subvariants (Omicron BA.2, BA.2.12.1, BA.4, and BA.5 subvariants)[10–12],
- FDA recommendations to increase dosage for Evusheld PrEP to 600 mg based on nonclinical data and pharmacokinetic modelling for these Omicron Subvariants[58],
- Emerging real-world data to support this increased dosage to prevent breakthrough infections. In one real-world study, solid-organ transplant recipients during the Omicron wave who received the 150– 150 mg dose had a higher incidence of breakthrough infections compared to those who received the 300– 300 mg dose (p = .025)[59],

And,

- the findings of the PROVENT trial[60],

We recommend that tixagevimab/cilgavimab at a dose of 300 mg of tixagevimab and 300 mg of cilgavimab may be considered for pre-exposure prophylaxis of COVID-19 in adults and paediatric (12 years of age and older and weighing at least 40kg) who are not currently infected with SARS CoV 2 and who have not had a known recent exposure to an individual infected with SARS CoV 2 who:

- 1) Have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID 19 vaccination (as evidenced by low/absent Anti-S antibody or neutralising antibody levels)

OR

- 2) Are not recommended for vaccination with **any** available COVID-19 vaccine, according to the approved or authorized schedule, due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID 19 vaccine(s) and /or COVID 19 vaccine component(s). This scenario is expected to be very uncommon because of the availability of multiple different formulations of COVID-19 vaccines.

Pre-exposure prophylaxis with tixagevimab-cilgavimab is **NOT** a substitute for vaccination in individuals for whom COVID 19 vaccination is recommended. Individuals for whom COVID 19 vaccination is recommended, including individuals with moderate to severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID 19 vaccination

In individuals who have received a COVID 19 vaccine, tixagevimab-cilgavimab should be administered at least two weeks after vaccination. In individuals which receive COVID-19

Monoclonal Antibodies (including tixagevimab/cilgavimab) COVID-19 vaccination should be deferred for 90 days.

Tixagevimab-cilgavimab pre-exposure prophylaxis may be prescribed by healthcare providers with Infectious Diseases approval or guidance (e.g. as part of institutional protocols, with ability to consult on individual cases if required), to ensure appropriate use.

### **POST-EXPOSURE PROPHYLAXIS**

Monoclonal antibodies may be considered as post-exposure prophylaxis for selected individuals at very high risk of disease progression. Their role in the general seronegative population is yet to be clearly defined.

The BLAZE-2 COVID-19 prevention trial found that, at 8-weeks follow-up, bamlanivimab lowered the frequency of symptomatic COVID-19 in a study which enrolled 966 participants (300 residents and 666 staff at skilled nursing and assisted living facilities) (8.5% vs 15.2%; odds ratio, 0.43 [95% CI, 0.28-0.68]).[61] Five deaths attributed to COVID-19 were reported by day 57; all occurred in the placebo group. This study was conducted from August to November 2020 – before the emergence of the Delta or Omicron variant and before implementation of COVID-19 vaccination programmes.

A similar study with REGEN-COV randomly assigned, 1555 participants ( $\geq 12$  years of age) within 96 hours after a household contact received a diagnosis of SARS-CoV-2 infection to receive 1.2g of REGEN-COV or matching placebo administered by means of subcutaneous injection. Symptomatic SARS-CoV-2 infection developed in 11 of 753 participants in the REGEN-COV group (1.5%) and in 59 of 752 participants in the placebo group (7.8%) (relative risk reduction [1 minus the relative risk], 81.4%;  $P < 0.001$ ). In weeks 2 to 4, a total of 2 of 753 participants in the REGEN-COV group (0.3%) and 27 of 752 participants in the placebo group (3.6%) had symptomatic SARS-CoV-2 infection (relative risk reduction, 92.6%). REGEN-COV also prevented symptomatic and asymptomatic infections overall (relative risk reduction, 66.4%).[61]

In June 2021, AstraZeneca announced results from the STORMCHASER trial assessing the safety and efficacy of tixagevimab-cilgavimab for the prevention of symptomatic COVID-19 in unvaccinated participants recently exposed to the SARS-CoV-2 virus (within 8 days of potential exposure).[62] The trial did not meet the primary endpoint of post-exposure prevention of symptomatic COVID-19 with tixagevimab-cilgavimab compared to placebo. In the overall trial population, tixagevimab-cilgavimab reduced the risk of developing symptomatic COVID-19 by 33% (95% confidence interval (CI): -26, 65) compared to placebo, which was not statistically significant. However, in a pre-planned analysis of SARS-CoV-2 PCR positive (detectable virus) and PCR negative (no detectable virus) participants, tixagevimab-cilgavimab reduced the risk of developing symptomatic COVID-19 by 73% (95% CI: 27, 90) compared with placebo, in participants who were PCR negative at time of dosing. In a post-hoc analysis, in participants who were PCR negative at baseline, tixagevimab-cilgavimab reduced the risk of developing symptomatic COVID-19 by 92% (95% CI: 32, 99) versus placebo for those who had an onset of COVID-19 more than seven days following dosing, and by 51% (95% CI: -71, 86) for an onset of COVID-19 up to seven days following

dosing. Tixagevimab-cilgavimab does not currently have an US FDA EUA or HSA indication for post-exposure prophylaxis of COVID-19.

Based on the above data, and the current circulating Omicron subvariants:

- We do not recommend the use of casirivimab-imdevimab as post-exposure prophylaxis
- Based on the data from the STORMCHASER trial, tixagevimab-cilgavimab which retains at least some Omicron activity in-vitro (<https://opendata.ncats.nih.gov/variant/activity>), *may* be considered for post-exposure prophylaxis (PEP) in high-risk patients (within 8 days of potential exposure) (Ungraded). Pending the availability of further clinical evidence, the dose for tixagevimab-cilgavimab, if used for PEP, should be the same as for PrEP, at 300 mg of tixagevimab and 300 mg of cilgavimab

Post-exposure prophylaxis *may* be considered for patients who were exposed to COVID-19 less than 8 days prior to administration, who are at higher risk of developing severe COVID-19 disease due to their age or comorbid conditions, and fulfil either (i), (ii) OR (iii)

- i. Age  $\geq$  65 **AND** Unvaccinated against SARS-CoV-2 (any PSAR or WHO EUL vaccine); **or** Vaccinated **AND** unable to mount an adequate immune response\*, **OR**
- ii. Immunocompromised per EC19V definition (any age) and unable to mount an adequate immune response\*, regardless of vaccination status, **OR**
- iii. Have pre-specified co-morbidities (pregnant, chrck kidney disease or ESRF on dialysis, diabetes mellitus, obesity, immunosuppressive disease or treatment, cardiovascular disease (including congenital heart disease), chronic lung disease, neurodevelopmental disorders/ genetic or metabolic syndromes or severe congenital abnormalities, medical-related technological dependence), **AND** unable to mount an adequate immune response\*, regardless of vaccination status

\*e.g. as evidenced by low/absent Anti-S or neutralizing antibodies

*While tixagevimab-cilgavimab has received PSAR authorisation for **pre-exposure prophylaxis (PrEP)** for COVID-19, it has not received PSAR authorisation for **post-exposure prophylaxis (PEP)** for COVID-19, as of the issuance date of this guidance. Based on available evidence, tixagevimab-cilgavimab may be considered for PEP, although it is considered 'off-label', and requesting doctors are fully responsible for the use of tixagevimab-cilgavimab on patients. Risk, benefits and potential adverse events (RBAE) should be discussed with patients and documented.*

## THERAPIES THAT ARE NOT RECOMMENDED OR HAVE INSUFFICIENT EVIDENCE FOR RECOMMENDATION

### **1. We do not recommend the routine use of convalescent plasma for the treatment of COVID-19. (Level I, Grade B, Moderate).**

Convalescent plasma has not been definitively shown to be effective as a treatment for COVID-19 and concerns remain regarding the risk and benefits of such treatment, in the light of available therapies which have proven efficacy in COVID-19. Efficacy is also uncertain, for example, of units collected prior to the emergence of VOCs, for treatment of disease caused by VOCs.

One RCT published (103 patients), with a primary outcome of time to clinical improvement within 28 days, defined as patient discharged alive or reduction of 2 points on a 6-point disease severity scale, but this trial was terminated early and was likely underpowered.[63] In this study, severe COVID-19 was defined as respiratory distress as indicated by  $\geq 30$  breaths/min; in resting state, oxygen saturation  $\leq 93\%$  on room air; or arterial partial pressure of oxygen (PaO<sub>2</sub>)/fraction of inspired oxygen (FiO<sub>2</sub>) of 300 or less. Life-threatening COVID-19 was defined as respiratory failure requiring mechanical ventilation; shock; or other organ failure (apart from lung) requiring intensive care unit (ICU) monitoring. There was no significant difference in the primary outcome in the convalescent plasma group 51.9% (27/52) vs 43.1% (22/51) in the control group (difference 8.8% [95% CI, -10.4% to 28.0%]; hazard ratio [HR], 1.40 [95% CI, 0.79-2.49]; P=0.26). In a post-hoc sub-analysis of those with severe disease, the primary outcome occurred in 91.3 % (21/23) of the convalescent plasma group vs 68.2 % (15/22) of the control group (HR, 2.15 [95% CI, 1.07-4.32]; P=0.03). No difference was found in the group with life-threatening disease, possibly because the trial was underpowered. At 24, 48 and 72 hours, the convalescent plasma group statistically significant a higher rate of viral nucleic acid negative conversion rate.

Another RCT consisting of 228 patients who received convalescent plasma versus 105 patients who received placebo found no significant difference between the groups in the distribution of clinical outcomes according to the ordinal scale at day 30 (odds ratio, 0.83; 95% CI 0.52 to 1.35; p=0.46). Overall mortality was 10.96% in the convalescent plasma group and 11.43% in the placebo group, for a risk difference of -0.46 percentage points (95% CI, -7.8 to 6.8).[64] Similarly, another trial conducted in India (PLACID), which was an open label phase II RCT comprising 464 patients failed to find benefit with convalescent plasma for a composite outcome of progression to severe disease (PaO<sub>2</sub>/FiO<sub>2</sub> <100 mm Hg) or all-cause mortality at 28 days post-enrolment.[65]

A retrospective US national registry based study comprising 3082 patients found a 30-day mortality rate after plasma transfusion in 115 of 515 patients (22.3%) in the high-titre group, 549 of 2006 patients (27.4%) in the medium-titre group, and 166 of 561 patients (29.6%) in the low-titre group, with a sub analysis showing no mortality benefit in those on mechanical ventilation.[66]

One randomized, double-blind, placebo-controlled trial (n=160) of convalescent plasma with high IgG titres against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in older adult patients within 72 hours after the onset of mild Covid-19 symptoms, however, found a reduction in the

progression of Covid-19 (severe respiratory disease) (relative risk, 0.52; 95% confidence interval [CI], 0.29 to 0.94;  $P = 0.03$ ), with a relative risk reduction of 48%.[67]

A large multicentre, double-blind, randomized, controlled trial[68] evaluated the efficacy and safety of COVID-19 convalescent plasma, as compared with control plasma in symptomatic adults ( $\geq 18$  years of age) who had tested positive for SARS-CoV-2, regardless of their risk factors for disease progression or vaccination status. Participants were enrolled within 8 days after symptom onset and received a transfusion within 1 day after randomization. Among 1225 participants who underwent randomization, 1181 received a transfusion. The primary outcome (COVID-19-related hospitalisation within 28 days after transfusion) occurred in 17 of 592 participants (2.9%) who received convalescent plasma and 37 of 589 participants (6.3%) who received control plasma (absolute risk reduction, 3.4 %; 95% confidence interval, 1.0 to 5.8;  $P = 0.005$ , relative risk reduction 54%). However, as all the patients in that study were recruited before the Omicron wave and were mainly unvaccinated, the results from this study may not be extrapolatable to the vast majority of patients currently. Of note, in the small subgroup of fully vaccinated patients, none in either arm of the study was hospitalised. In addition, plasma infusion was associated with transfusion adverse events (5.7% in the convalescent plasma group and 9.3% in the control group).

In terms of safety there is theoretical risk of exacerbating lung injury secondary to immune-enhancement, but a large study on key safety metrics after transfusion of ABO-compatible human COVID-19 convalescent plasma in 20,000 hospitalised adults with severe or life-threatening COVID-19 as part of the US FDA Expanded Access Program for COVID-19 convalescent plasma found the incidence of all serious adverse events (SAEs) in the first four hours after transfusion to be  $<1\%$ .[69]

Considering the available evidence, and given the availability of other effective treatments, we do not recommend the routine use of convalescent plasma for the treatment of COVID-19. The convalescent plasma programme in Singapore has ceased prospective collection of units and was suspended in September 2021.

**2. We do not recommend the use of interferon preparations (e.g. interferon beta-1a/1b, interferon alpha-2b) (Level II, Grade C, Weak) or lopinavir/ritonavir (Level I, Grade B, Strong), outside of a clinical trial.**

In a phase 2 RCT in 125 adults in Hong Kong, combination treatment (lopinavir/ritonavir and ribavirin, with interferon beta-1b if within 7 days of onset of illness, was found to have more rapid nasopharyngeal virologic clearance (7 vs. 12 days) [the study's primary end point], shorter time to symptom alleviation (4 vs. 8 days), and shorter median hospital stay (9 vs. 15 days).[70] In a subgroup analysis, patients in the combination therapy group who did not receive interferon did not have better outcomes than the control group, suggesting that interferon may be the backbone of this treatment, and further studies are planned. Patients had mild COVID-19 in both combination and control groups in this trial, however, as indicated by a median NEWS score of 2. One small open-label RCT comprising 81 patients found that early administration of interferon beta-1a subcutaneously at 12 million IU/ml 3 times weekly for 2 consecutive weeks (before 10 days from onset of symptoms) reduced mortality (OR 13.5, 95% CI 1.5-118), and overall 28-day mortality (19% vs 43.6,  $P = 0.015$ ).[71] However, the

WHO-sponsored SOLIDARITY trial, comprising 11,330 adults (and 2063 to interferon beta-1a) also failed to show a mortality benefit, or reduction in ventilation or hospitalization duration in patients receiving interferon beta-1a,[34] and another multi-centre randomized controlled trial involving 969 patients from 5 countries found that interferon beta-1a plus remdesivir was not superior to remdesivir alone in hospitalised patients with COVID-19 pneumonia.[72]

The LOTUS trial which was a non-blinded RCT on lopinavir/ritonavir monotherapy with 199 patients with more severe COVID-19 (overall mortality 22%), showed that time to clinical improvement did not differ between the two groups (median, 16 days), and the mortality rate at 28 days was numerically lower for lopinavir/ritonavir compared with standard care (19.2% vs 25%, -5.8 percentage points; 95% CI, -17.3 to 5.7) but this did not reach statistical significance.[73] In a modified intention-to-treat analysis, which excluded three patients with early death, the between-group difference in the median time to clinical improvement (median, 15 days vs. 16 days) was significant, albeit only very modest (hazard ratio, 1.39; 95% CI, 1.00 to 1.91), and this did not clearly correlate with virologic clearance.[73]

Based on these results, as well as the results from the RECOVERY and SOLIDARITY trials, we do not recommend interferons or lopinavir/ritonavir as therapy outside of a clinical trial.

### **3. We do not recommend the use of fluvoxamine for the treatment of COVID-19 (Level II, Grade B, Weak), outside of a clinical trial.**

One preliminary RCT, STOP-COVID, with a small cohort (n=152) and limited follow up found a lower likelihood of deterioration over 15 days with fluvoxamine[74], and another RCT (TOGETHER, 741 randomised to fluvoxamine and 756 to placebo) found that treatment with fluvoxamine 100 mg twice daily for 10 days in high-risk outpatient with early COVID-19 reduced the need for hospitalisation (defined as retention in a COVID-19 emergency setting >6 hours or transfer to a tertiary hospital up to 28 days post-randomisation (111% vs 16%, RR 0.68, 95% CI 0.52-0.88).[75] The significance of the TOGETHER trial's end point (> 6 hours retention in the emergency room) and its broader applicability may be limited, and a follow on trial examining the utility of fluvoxamine (STOP-COVID 2) was stopped early for futility due to low case rates and recruitment, and no differences found between fluvoxamine and placebo up to the time of trial cessation.[76] Another RCT with a 2-by-3 factorial design, COVID-OUT found no benefit of fluvoxamine, or ivermectin or metformin in preventing serious SARS-CoV-2 infection (hypoxemia, emergency room visit, hospitalization or death) in patients enrolled within 3 days of a confirmed infection and less than 7 days after onset of symptoms.[77]

### **4. We do not recommend the use of inhaled corticosteroids (e.g. budesonide) for the treatment of COVID-19 (Level II, Grade B, Weak), outside of a clinical trial.**

The PRINCIPLE trial was an open label RCT (n=1856) which found a decreased time to self-reported recovery with the inhaled budesonide arm (11.8 days vs 14.7 days), but no difference in 28 days mortality or hospitalisation.[78] The open label nature and the end-point of self-reported recovery limits the generalisability and significance of this trial. The STOIC trial included 146 patients and looked at an endpoint of COVID-19 related urgent care visit or hospitalisation and found a reduction in the

primary outcome of 3% in budesonide arm vs 15% in usual care arm ( $P=0.009$ , ITT) but this was a small trial and further RCTs are needed.[79]

**5. We do not recommend the use of hydroxychloroquine or chloroquine for the treatment of COVID-19 (Level I, Grade A, Strong).**

A small study of 20 COVID-19 patients treated with hydroxychloroquine +/- azithromycin by a French group generated interest as it showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine (in six of 20 patients) was reported to more effectively clear the virus. However numerous concerns were raised with this trial, in particular its open-label and non-randomized nature and small number of patients.[80]

One large purported registry study has been retracted due to doubts over the veracity of data,[81] several large observational trials have since shown no clear benefit and a potential for cardiac toxicity,[82–85] in particular when hydroxychloroquine is combined with azithromycin. Additionally, the RECOVERY trial interim analysis of 1542 patients who were randomised to hydroxychloroquine, compared with 3132 patients randomised to usual care alone found no significant difference in the primary endpoint of 28-day mortality (25.7% hydroxychloroquine vs. 23.5% usual care; hazard ratio 1.11 [95% CI 0.98-1.26];  $P=0.10$ ), and no evidence of beneficial effects on hospital stay duration.[86] The SOLIDARITY trial also failed to show any benefit of hydroxychloroquine on mortality, need for mechanical ventilation or hospitalization duration.[34] We therefore do not recommend the use of hydroxychloroquine or chloroquine.

**6. We do not recommend the use of favipiravir outside of a clinical trial (Level II, Grade B, Weak).**

One prospective, open-label, RCT of favipiravir in Japan comprising 89 patients randomised to get favipiravir early (day 1) or late (day 6) did not find differences in times to defervescence, viral clearance, disease progression or 28-day mortality.[87] An adaptive, multicentre, open label phase II/III RCT of favipiravir vs standard of care in hospitalised patients with moderate COVID-19 pneumonia reported interim results consisting of 60 patients enrolled in the pilot stage.[88] On day 5, the viral clearance was achieved in 25/40 (62.5%) patients on favipiravir and in 6/20 (30.0%) patients on standard of care ( $p=0.018$ ). By day 10, the viral clearance was achieved in 37/40 (92.5%) patients on favipiravir and in 16/20 (80.0%) patients on standard of care. The median time to body temperature normalization was 2 days (IQR 1–3) in the favipiravir group and 4 days (IQR 1–8) in the standard of care group ( $p=0.007$ ). A recent meta-analysis showed faster viral clearance at day 7 with favipiravir, and clinical improvement by day 14, but studies included were heterogenous in design and no difference in mortality was noted.[89]

Evidence of significant clinical benefit of favipiravir is still lacking and we do not recommend its use outside of a clinical trial.

**7. We do not recommend the use of other non-corticosteroid immunomodulators (e.g. IL-1, BTK, GM-CSF inhibitors) outside of a clinical trial. (Ungraded).**

Besides corticosteroids, tocilizumab and the JAK inhibitors e.g. baricitinib, tofacitinib, the role of non-steroid immunomodulators in the treatment of COVID-19 is still unclear., e.g. IL-1, and other immunomodulators e.g. BTK inhibitors are unclear at this point.[90,91] Further data are awaited.

Anti-Granulocyte macrophage colony-stimulating factor (GM-CSF) monoclonal antibodies directly binds GM-CSF and prevents signalling through its receptor, and downstream activation and trafficking of myeloid cells and elevation of chemokines (e.g. IP-10, MCP-1, IL-8), cytokines (IL-6, IL-1) and other markers of systemic inflammation (CRP, D-dimer, ferritin) and various anti-GM-CSF antibodies have been studied including lenzilumab, mavrilimumab, and otilimab. Lenzilumab improved the likelihood of survival without ventilation by 54% in the mITT population (HR: 1.54; 95%CI: 1.02-2.31, p=0.041, preprint data)[92], and there were some indications in a preplanned sub analysis in a otilimab trial for a survival benefit in patients  $\geq 70$  years (65.1% with otilimab vs 45.9% in placebo, P = 0.009)[93], but this was an unadjusted analyses, and no mortality benefit was found in a small trial (n=40) with mavrilimumab.[94] Further data are needed for the anti-GM-CSF antibodies.

**8. We do not recommend the use of cellular therapies such as mesenchymal stem cell infusion or donor lymphocyte infusions outside of a clinical trial (Level II, Grade C, Weak).**

Few data are available for lymphocyte infusion therapies[95] and larger confirmatory trials are needed for mesenchymal stem cell infusion therapy.[96,97]

**9. We do not recommend the use of ivermectin for the treatment or prophylaxis for COVID-19 (Level I, Grade A, Strong).**

Many clinical studies have limitations such as methodological limitations including small sample sizes, varying dosing regimens of ivermectin, open-label design, and poorly defined disease severity and outcome measures. One RCT of 476 patients with mild COVID-19 did not find any difference in time to symptom resolution with a 5-day course of ivermectin, compared to placebo.[98] In another open-label RCT (n=490) of high-risk patients with mild to moderate COVID-19 conducted in Malaysia, oral ivermectin at 0.4mg/kg body weight daily for 5 days in early illness did not prevent progression to severe disease.[99] An RCT in Singapore also did not show a protective effect of a single 12 mg dose of oral ivermectin in preventing COVID-19.[100] Toxicities associated with misuse and overdose include rash, nausea, vomiting, abdominal pain, severe hepatitis, and even death. The COVID-OUT RCT also did not find benefit of ivermectin in preventing serious SARS-CoV-2 infection. [77]

**10. We do not recommend post- or pre- exposure chemoprophylaxis for COVID-19 with hydroxychloroquine (Level I, Grade B, Moderate).**

One RCT involving 821 subjects found no benefit with post-exposure prophylaxis,[101] although this study had some limitations (only 15% of COVID-19 cases confirmed by PCR, and a delay of 3 or more days between exposure and starting preventive treatment). Another randomised controlled trial conducted in Singapore with 3037 participants in a dormitory setting with a COVID-19 outbreak,

looked at hydroxychloroquine, iodine-spray and Vitamin C/Zinc, and found absolute risk reductions of COVID-19 infection with oral hydroxychloroquine (21%, 2–42%) and povidone-iodine throat spray (24%, 7–39%).[100] This trial was however, open label, and cluster-randomised (not individually randomised) and infection-pressure might not have been homogenous across groups. A separate meta-analysis (not including the Singaporean study[100]) of over 4000 participants in 4 studies found that hydroxychloroquine might have trivial to no effect on suspected, probable, or laboratory confirmed infection.[102] The pre-exposure prophylaxis trial with hydroxychloroquine, Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine [HERO-HCQ] results only enrolled 1360 of a planned 15,000 health care workers and was terminated, and failed to find any benefit (albeit underpowered)[103].

## THROMBOPROPHYLAXIS AND THERAPEUTIC ANTICOAGULATION TO REDUCE DISEASE PROGRESSION AND ADVERSE CLINICAL OUTCOMES IN COVID-19 PATIENTS

### Thromboprophylaxis

**We recommend the use of pharmacological venous thromboembolism (VTE) prophylaxis for patients with critical or severe COVID-19. We recommend patient risk stratification with the PADUA risk score for patients with mild/moderate COVID-19, in determining whether pharmacological thromboprophylaxis is warranted. If pharmacological prophylaxis is contra-indicated, mechanical prophylaxis is recommended (Level 1, Grade A, Strong).**

This recommendation represents good clinical practice in the intensive care setting, and is in keeping with international guidelines [104,105] based on RCTs which in absolute and relative terms, have demonstrated that pharmacological prophylaxis reduces mortality, pulmonary embolism, and deep vein thrombosis. COVID-19 is associated with thromboembolic disease as a result of various factors, including endothelitis associated with COVID-19, an increase in circulating prothrombotic factors, and immobility in critical illness.[104,105] D-dimer should not be used as a screening tool for VTE; instead, it should be used as a diagnostic tool of exclusion. Higher rates of thrombosis are seen in ICU COVID-19 patients, in studies that systematically evaluate for them.[106–110]

All COVID-19 patients should have thrombotic and bleeding risk assessments such as PADUA score (<https://www.mdcalc.com/padua-prediction-score-risk-vte>) and VTE bleed score ([https://practical-haemostasis.com/Clinical%20Prediction%20Scores/Formulae%20code%20and%20formulae/Formulae/VTED\\_bleedng/vte\\_bleed\\_score.html](https://practical-haemostasis.com/Clinical%20Prediction%20Scores/Formulae%20code%20and%20formulae/Formulae/VTED_bleedng/vte_bleed_score.html)), or any Risk Assessment Model that the hospital uses, upon diagnosis and as part of the admission process for COVID-19 patients in both acute hospitals and also at out-of-hospital isolation facilities (e.g. Community Care Facilities). In the absence of a locally validated scoring system, we propose to adopt PADUA risk stratification, acknowledging that it has not been extensively validated in the Asian/Singaporean population. Persons at high risk of VTE (such as PADUA score  $\geq 4$  points) should be assessed for thromboprophylaxis with an appropriate agent and duration at an acute hospital. In patients with severe COVID-19 infection, we recommend pharmacological thromboprophylaxis unless contraindicated as they are at higher risk of thrombotic

events.[111] In patients with mild/moderate COVID-19 infection, we recommend risk stratification of patients, such as with the PADUA risk score, to determine whether pharmacological thromboprophylaxis is warranted. In patients with contraindications to pharmacological thromboprophylaxis, the use of pneumatic calf pumps is recommended.

As a general guidance, persons with high risk of VTE (such as PADUA score  $\geq 4$  points) be administered thromboprophylaxis with SC enoxaparin 40mg once daily (or renal adjusted dose of 20mg once daily) or other low molecular weight heparin (LMWH), until discharge (i.e. from acute hospital or the out-of-hospital facility if transferred from an acute hospital, whichever is later). If patients are discharged to an out-of-hospital facility, where they have to self-administer LMWH, they should receive the appropriate training and education prior to transfer.

Patients should be educated on general measures to prevent thromboembolism or seek urgent consultation for symptoms of thromboembolism. Patients should be encouraged to maintain hydration and to avoid immobility, so as to reduce the risk of thromboembolism.

We recommend that treating clinicians have a high index of suspicion and low threshold for imaging in situations where VTEs are suspected, such as when heart rate  $\geq 100$  beats/min, oxygen saturation  $< 94\%$  on room air, or desaturations on exercise). For lower limb DVT or PE provoked by COVID-19, the recommended length of treatment is 3 months.

Routine antiplatelet treatment for all COVID-19 recovered patients is not recommended – the RECOVERY trial found no benefit on 28-day mortality or in the risk of progressing to invasive mechanical ventilation or death with aspirin dosed at 150 mg per day till discharge vs placebo.[112]

### **Therapeutic anticoagulation**

Several recent trials (REMAP-CAP/ATTACC/ATIV-4A[113], INSPIRATION[114]) found no benefit of therapeutic anticoagulation doses of heparin, or doses higher than for prophylaxis, in critically ill patients with COVID-19, but benefit in hospitalised non-ICU patients (REMAP-CAP/ATTACC/ATIV-4A, RAPID[115], HEP-COVID[116]). This benefit in the REMAP-CAP/ATTACC/ATIV-4A trial was a primary outcome was a composite of 21-day “organ-support-free” days, defined as the number of hospital days not requiring high-flow nasal oxygen, invasive or non-invasive mechanical ventilation, vasopressor therapy, extracorporeal membrane oxygenation (ECMO) support together with in-hospital mortality, for the RAPID trial was a composite of death, invasive mechanical ventilation, non-invasive mechanical ventilation, or admission to an intensive care unit, assessed up to 28 days, and for the HEP-COVID trial was venous thromboembolism (VTE), arterial thromboembolism (ATE), or death from any cause, at  $30 \pm 2$  days.

Although benefit of therapeutic heparin was shown in the three RCTs in hospitalised non-ICU patients (REMAP-CAP/ATTACC/ATIV-4A, RAPID, HEP-COVID), and some guidance (e.g. IDSA/NIH/ASH guidelines) have recommended the consideration of therapeutic doses of heparin-anticoagulation in this group), the interpretation and wide-spread applicability of the results are complicated by[117]:

- Different trial inclusion criteria

- Different definitions of positive outcomes
  - Differences in control group anticoagulant intensity across trials
  - Significant proportions of patients receiving anticoagulant doses higher or lower than the assigned treatment and thus complicating interpretation of results, for e.g. in the largest trial (REMAP-CAP/ATTACC/ATIV-4A), 28.2 percent assigned to the standard care arm received higher than prophylactic dose heparin and 20.3 percent assigned to therapeutic dose heparin received a lower dose.
  - Unclear risk/benefits in different or real-life populations. The largest trial (REMAP-CAP/ATTACC/ATIV-4A) found an absolute risk difference for progression to organ support or death at 21 days at only 4 percent, with a 1 percent major bleeding rate, diminishing possible risk/benefits. The trial also was not able to specify the most common reasons for exclusion (e.g. bleeding risk).
    - The improved clinical outcome in these trials were contributed mainly by reduced thrombotic events brought about by therapeutic dose of heparins,
    - The decrease in mortality in the (REMAP-CAP/ATTACC/ATIV-4A) trial is likely been contributed significantly by reduced venous or arterial thrombotic complications.
    - In the HEP-COVID trial (, the better composite outcome is **mainly** driven by the reduction of venous and arterial thrombotic events, with no difference in mortality rates between the study and control groups.
    - Patients in Singapore are documented to have much lower thrombotic rates as compared to Caucasian patients, and thus these results is not applicable to local Asian population.[118–120] Indeed in the RAPID trial, subgroup analysis based on race and ethnicity showed no difference in composite outcome seen in the Asians receiving therapeutic doses of LMWH.
- The time period of these studies was prior to the emergence of the Omicron VOC and many instances prior to the Delta VOC, which may have quite different clinical characteristics
- Patients enrolled were mostly non-vaccinated (or enrolled in the period prior to widespread vaccination)

**Given the above these guidelines and the COVID-19 Thrombosis Workgroup do not recommend therapeutic anticoagulation for patients with mild-moderate COVID-19 infection, but prophylactic anticoagulation for patients assessed to be at increased risk of developing venous thrombosis.**

## SPECIAL POPULATIONS: PAEDIATRIC PATIENTS, PREGNANT WOMEN, IMMUNOCOMPROMISED HOSTS

### ***Paediatric patients***[121]

Remdesivir: Remdesivir may be considered for children with COVID-19 weighing  $\geq 3$  kg who have risk factors for severe disease, have an increasing need for supplemental oxygen, have a SpO<sub>2</sub> of  $<94\%$  on room air, or who have severe or critical illness. There is currently a lack of data for neonates and very young infants. The FDA in April 2022 approved a supplemental new drug application (sNDA) for remdesivir for the treatment of paediatric patients who are older than 28 days and weighing  $\geq 3$  kg, who are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered

high risk for progression to severe COVID-19, including hospitalization or death. This was supported by data from the CARAVAN trial ( NCT 004431453).

Remdesivir dosing for children weight  $\geq 3$  kg to  $<40$ kg: Loading dose: IV 5mg/kg/dose Q24H on Day 1, followed by maintenance dose of IV 2.5mg/kg/dose Q24H from Day 2 onwards. Refer to adult dosing for  $\geq 40$ kg.

Dexamethasone: Children with clinically significant or worsening COVID-19 pulmonary or systemic disease should be given oxygen and/or supportive treatment, Dexamethasone 0.15 mg/kg IV or orally once daily (maximum dose 6 mg) (or equivalent steroid) can be considered in children who require oxygen (e.g. high-flow oxygen, non-invasive, invasive mechanical ventilation), or on a case-by-case basis otherwise.

Monoclonal antibodies (e.g. sotrovimab, tixagevimab-cilgavimab) and nirmatrelvir-ritonavir: May be considered on a case-by-case basis for children who are at high risk for severe disease who are  $\geq 12$  years and  $\geq 40$  kg. Additional trials are underway (e.g. NCT 05124210 COMET-PACE). **Molnupiravir should not be used in patients  $<18$  years.**

Other immunomodulators (Baricitinib and Tocilizumab): There is very limited paediatric data and insufficient evidence to make a formal recommendation. Tocilizumab if used should be used in combination with a glucocorticoid.

COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C): Should be managed by experienced paediatricians, and IVIG plus methylprednisolone is recommended. In refractory MIS-C, high-dose anakinra, higher dose glucocorticoids, tocilizumab or infliximab may be considered. Low dose aspirin should be initiated for all patients without risk for bleeding. For children with coronary artery aneurysms, moderate to severe left ventricular dysfunction, therapeutic anticoagulation should be considered. Otherwise anticoagulation at prophylactic doses should be considered in the presence of specific risk factors.

Treating physicians should refer to Paediatric Infectious Disease specialists and their respective institutional guidelines.

### ***Pregnant women***

The specific therapies for COVID-19 in pregnant patients should follow that of nonpregnant patients, Treatment for COVID-19 should not be withheld from pregnant or lactating individuals because of theoretical safety concerns.

Remdesivir: Remdesivir was not studied specifically in the trials that led to its approval, however data from 86 pregnant and postpartum hospitalised patients with severe COVID-19 treated with remdesivir on a compassionate use programme found that it was well tolerated with minimal serious adverse events (16%, mostly grade 1/2 laboratory abnormalities).[117] At Day 28 of follow-up, among pregnant women (n=67), and among postpartum women (n=19, all immediate postpartum, median

duration post-delivery, 1 day), respectively, 93% and 89% of those on mechanical ventilation were extubated, 93% and 89% recovered, and 90% and 84% were discharged.

Steroids: Dexamethasone has a history of use to decrease neonatal complications in premature delivery and used for foetal lung maturity have not been associated with ill-effects. There is however some concern of potential adverse foetal effects (e.g. small head circumference, growth restriction, and neonatal hypoglycaemia) with repeated doses of antenatal glucocorticoids. Further there is less data of corticosteroids for pregnant women with COVID-19 (e.g. only 6 pregnant women were enrolled in the RECOVERY trial). However, given the benefits, we recommend the use of steroids for pregnant women with severe or critical COVID-19.

Prednisolone, methylprednisolone and hydrocortisone are metabolised by the placenta and have limited foetal transfer. Dexamethasone (and betamethasone) cross the placenta and have substantial foetal transfer. Methylprednisolone and dexamethasone have the most data for benefit in acute lung injury.

As such, we recommend the algorithm suggested by Saad et al,[122] with the choice and duration of steroids in a pregnant patient with COVID-19 will depending on whether glucocorticoids are indicated for foetal lung maturity.

Pregnant patient with severe or critical COVID-19, requiring oxygen therapy and/or mechanical ventilation:

Glucocorticoids indicated for foetal lung maturity?	Steroid regimen
Yes (24 weeks to 33 weeks of gestation)	Dexamethasone 6 mg IM q12hourly for 4 doses, then switch to methylprednisolone 32 mg daily (oral or IV) to complete a total of 10 days or until recovery/discharge (whichever comes first)
No (outside 24 to 33 weeks of gestation, or post-partum and breastfeeding)	Methylprednisolone 32 mg daily (oral or IV) to complete a total of 10 days or until recovery/discharge (whichever comes first)

General comments on the management of pregnant women:

Maternal SpO<sub>2</sub> should be kept at least 95% and above, PaO<sub>2</sub> above 70 mmHg to maintain sufficient oxygen diffusion gradient across the placenta to the foetus. Hypoxia in adults is defined as  $\leq 94\%$ .

Prone positioning may be difficult in pregnant patient in later trimesters due to aortocaval compression. Left lateral position may be an alternative if proning not feasible for pregnant woman with COVID-19 related ARDS.

VTE prophylaxis in pregnant women with COVID-19 is an individualized decision and should be considered for those with severe COVID-19. Unfractionated heparin may be preferred for those closer to delivery as it is more readily reversed.

### ***Immunocompromised hosts***

In select patients (e.g. immunocompromised hosts), humoral therapies (e.g. monoclonals) or anti-virals may be deployed beyond the usual durations studied in trials, but this should be a shared-decision between infectious diseases physician and the primary specialist managing the immunocompromised patient.[123–126]

Please note that the recommendations above are based on current data, and that updates will be made to this guidance as more evidence becomes available. **Clinical evidence summaries for various therapeutics for COVID-19 are also available from the Ministry of Health-Agency for Care Effectiveness at <https://www.moh.gov.sg/covid-19/clinical-evidence-summaries> and US-NIH <https://www.covid19treatmentguidelines.nih.gov/>.**

### **References**

1. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. *N Engl J Med* **2021**; :1–12.
2. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *N Engl J Med* **2022**; :1–12.
3. Arbel R, Health Services Yael Wolff Sagy C, Hoshen M, Lavie Clalit Health Services Ruslan Sergienko Ben- G, Friger Ben- M. Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron Surge. *Clalit Heal Serv Shlomit Yaron Clalit Heal Serv Danielle Serby Clalit Heal Serv Ariel Hammerman Clalit Heal Serv Doron Netzer Clalit Heal Serv Res Artic* **2022**; :1–9. Available at: <https://doi.org/10.21203/rs.3.rs-1705061/v1>.
4. Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND XR. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. *medRxiv* **2022**; :doi: 10.1101/2022.06.21.22276724.
5. Ranganath N, O’Horo JC, Challener DW, Tullidge-Scheitel SM, Pike ML, Michael O’Brien R, Razonable RR SA. Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons. *Clin Infect Dis* **2022**; :2022 Jun 14:ciac481. doi: 10.1093/cid/ciac481. Epub.
6. Rinki Deo, Manish C. Choudhary, Carlee Moser, Justin Ritz, Eric S. Daar, David A. Wohl, Alexander L. Greninger, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, Davey M. Smith, Kara W. Chew JZL. Viral and Symptom Rebound in Untreated COVID-19 Infection 2. *medRxiv* **2022**; :doi: <https://doi.org/10.1101/2022.08.01.22278278>.
7. Ryan P, Nielsen BU, Brown M, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. **2021**; :1–11.
8. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial. *JAMA - J Am Med Assoc* **2020**; 324:1048–1057.
9. Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Respir Med* **2022**; 19.
10. Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, Fukushi S, Suzuki T, Maeda K, Halfmann P, Sakai-Tagawa Y, Ito M, Watanabe S, Imai M, Hasegawa H KY. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. *N Engl J*

Med **2022**; 387:468–470.

11. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. *Nature* **2022**;
12. Yamasoba D, Kosugi Y, Kimura I, Fujita S, Uriu K, Ito J SK. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. *Lancet Infect Dis* **2022**; 22:942–943.
13. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. *N Engl J Med* **2021**; 385:1941–1950.
14. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19. *Jama* **2022**; 98109.
15. Australia Government Department of Health. TGA receives application for an increased dose of GlaxoSmithKline’s COVID-19 treatment sotrovimab (XEVUDY) for the BA.2 Omicron sublineage. 2022. Available at: <https://www.tga.gov.au/media-release/tga-receives-application-increased-dose-glaxosmithklines-covid-19-treatment-sotrovimab-xevudy-ba2-omicron-sublineage>.
16. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H KY. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. **2022**; :1–3.
17. GSK. Primary endpoint met in COMET-TAIL Phase III trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19. 2022. Available at: <https://www.gsk.com/en-gb/media/press-releases/primary-endpoint-met-in-comet-tail-phase-iii-trial-evaluating-intramuscular-administration-of-sotrovimab-for-early-treatment-of-covid-19/>.
18. RECOVERY Trial. Intervention Sotrovimab 1000 mg once; Summary of information on sotrovimab in COVID-19. 2021. Available at: <https://www.recoverytrial.net/files/recovery-intervention-sheet-sotrovimab-v1-0.pdf>.
19. Ong SWX, Ren D, Lee PH, et al. Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients : An Observational Cross-Sectional Study. *Antibiotics* **2022**; 11:345. Available at: <https://doi.org/10.3390/antibiotics11030345>.
20. Westendorf K, Wang L, Žentelis S, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. *bioRxiv Prepr Serv Biol* **2022**; 1404. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/33972947%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC8109210>.
21. The COVID-19 Treatment Guidelines Panel’s Statement on the Role of Bebtelovimab for the Treatment of High-Risk, Nonhospitalized Patients With Mild to Moderate COVID-19. Available at: <https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-bebtelovimab/>.
22. Parry H, McIlroy G, Bruton R, et al. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. *Blood Cancer J* **2021**; 11:4–11. Available at: <http://dx.doi.org/10.1038/s41408-021-00528-x>.
23. GenScript. cPass SARS-CoV-2 Neutralization Antibody Detection Kit - Instructions for Use. **2021**; :1–38.
24. Ye, ZK, Wang Y, Colunga-Lozano L et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. *Cmaj* **2020**; 192:E756-67.

25. Yao TC, Huang YW, Chang SM, Tsai SY, Wu AC, Tsai HJ. Association between oral corticosteroid bursts and severe adverse events: A nationwide population-based cohort study. *Ann Intern Med* **2020**; 173:325–330.
26. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med* **2021**; 384:693–704.
27. Ranjbar K, Moghadami M, Mirahmadizadeh A, et al. Correction to: Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial (*BMC Infectious Diseases*, (2021), 21, 1, (337), 10.1186/s12879-021-06. *BMC Infect Dis* **2021**; 21:1–8.
28. Sterne JAC, Murthy S, Diaz J V., et al. Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Meta-analysis. *JAMA - J Am Med Assoc* **2020**; 324:1330–1341.
29. Munch MW, Myatra SN, Vijayaraghavan BKT, et al. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive without Life Support in Adults with COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. *JAMA - J Am Med Assoc* **2021**; 326:1807–1817.
30. Taboada M, Rodríguez N, Varela PM, et al. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 Pneumonia: an open-label, randomised clinical trial . *Eur Respir J* **2021**; :2102518.
31. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Final Report. *N Engl J Med* **2020**; 383:1813–1826.
32. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. *N Engl J Med* **2020**; 383:1827–1837.
33. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhan WC. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. **2020**; :19–21.
34. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. *N Engl J Med* **2021**; 384:497–511.
35. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Muller WJ, O’Horo JC, Shoham S, Murad MH, Mustafa RA, Sultan S F-YY. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. **2020**; :1–7.
36. Garibaldi BT, Wang K, Robinson ML, Betz J, Alexander GC, Andersen KM, Joseph CS, Mehta HB, Korwek K, Sands KE, Fisher AM, Bollinger RC XY. Real-World Effectiveness Of Remdesivir In Adults Hospitalized With Covid-19: A Retrospective, Multicenter Comparative Effectiveness Study. *Journals Gerontol Ser A Biol Sci Med Sci* **2018**; 0813:1–11.
37. Garibaldi BT, Wang K, Robinson ML, et al. Comparison of Time to Clinical Improvement with vs without Remdesivir Treatment in Hospitalized Patients with COVID-19. *JAMA Netw Open* **2021**; 4:1–14.
38. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *N Engl J Med* **2021**; 384:795–807.
39. Marconi VC, Ramanan A V., de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group,

- placebo-controlled phase 3 trial. *Lancet Respir Med* **2021**; 9:1407–1418.
40. Abani O, Abbas A, Abbas F, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* **2022**; 399:665–676.
  41. Self WH, Sandkovsky U, Reilly CS, et al. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BII-196 plus BII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. *Lancet Infect Dis* **2021**; 19:1–14.
  42. ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. *Lancet Respir Med* **2022**; 19:1–13. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/35817072>.
  43. Shankar-Hari M, Vale CL, Godolphin PJ, et al. Association between Administration of IL-6 Antagonists and Mortality among Patients Hospitalized for COVID-19: A Meta-analysis. *JAMA - J Am Med Assoc* **2021**; 326:499–518.
  44. Ghosn L, Chaimani A, Evrenoglou T, Davidson M, Graña C, Schmucker C, Bollig C, Henschke N, Sguassero Y, Nejstgaard CH, Menon S, Nguyen TV, Ferrand G, Kapp P, Riveros C, Ávila C, Devane D, Meerpohl JJ, Rada G, Hróbjartsson A, Grasselli G, Tovey D, Ravaud P BI. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. *Cochrane Database Syst Rev* **2021**; 3:CD013881. Available at: <https://www.medrxiv.org/content/10.1101/2021.11.05.21265656v1>.
  45. Abani O, Abbas A, Abbas F, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* **2021**; 397:1637–1645.
  46. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *N Engl J Med* **2021**; 384:1491–1502.
  47. Rosas IO, Diaz G, Gottlieb RL, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. *Intensive Care Med* **2021**; 47:1258–1270. Available at: <https://doi.org/10.1007/s00134-021-06507-x>.
  48. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P. Effect of Tocilizumab vs Usual Care in Adults Hospitalized with COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. *JAMA Intern Med* **2021**; 181:32–40.
  49. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. *N Engl J Med* **2021**; 384:1503–1516.
  50. Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. *N Engl J Med* **2021**; 384:20–30.
  51. Salvarani C, Dolci G, Massari M, et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized with COVID-19 Pneumonia: A Randomized Clinical Trial. *JAMA Intern Med* **2021**; 181:24–31.
  52. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. *N Engl J Med* **2020**; 383:2333–2344.
  53. Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: Randomised controlled trial. *BMJ* **2021**; 372.
  54. Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in

- patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. *Lancet Respir Med* **2021**; 9:511–521. Available at: [http://dx.doi.org/10.1016/S2213-2600\(21\)00081-3](http://dx.doi.org/10.1016/S2213-2600(21)00081-3).
55. Ely EW, Ramanan A V, Kartman CE, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. *Lancet Respir Med* **2022**; 2600:1–10.
  56. Levin MJ, Ustianowski A, De Wit S et al. LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/ Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults. *Open Forum Infect Dis* **2021**; 8 (Suppl 1):S810.
  57. AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19. Available at: <https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-prophylaxis-trial-met-primary-endpoint.html>. Accessed 5 March 2022.
  58. FDA. FDA authorizes revisions to Evusheld dosing. 2022. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing>.
  59. Al Jurdi A, Morena L, Cote M, Bethea E, Azzi J RL. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. *Am J Transplant* **2022**; Jun 21. doi.
  60. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19. *N Engl J Med* **2022**; 386:2188–2200.
  61. Cohen MS, Nirula A, Mulligan MJ, et al. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. *JAMA - J Am Med Assoc* **2021**; 326:46–55.
  62. Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19. 2021. Available at: <https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-azd7442-storm-chaser-trial.html>.
  63. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *JAMA - J Am Med Assoc* **2020**; 324:460–470.
  64. Simonovich VA, Burgos Pratx LD, Scibona P, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. *N Engl J Med* **2021**; 384:619–629.
  65. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial). *BMJ* **2020**; 371:1–10.
  66. Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. *N Engl J Med* **2021**; 384:1015–1027.
  67. Libster R, Pérez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *N Engl J Med* **2021**; 384:610–618.
  68. Sullivan DJ, Gebo KA, Shoham S, et al. Early Outpatient Treatment for Covid-19 with Convalescent Plasma. *N Engl J Med* **2022**; :1–12.
  69. Joyner MJ, Bruno KA, Klassen SA, et al. Safety Update: COVID-19 Convalescent Plasma in 20,000

- Hospitalized Patients. *Mayo Clin Proc* **2020**; 95:1888–1897.
70. Hung IFN, Lung KC, Tso EYK, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet* **2020**; 395:1695–1704. Available at: [http://dx.doi.org/10.1016/S0140-6736\(20\)31042-4](http://dx.doi.org/10.1016/S0140-6736(20)31042-4).
  71. Davoudi-monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M. A Randomized Clinical Trial of the Efficacy and Safety of Interferon  $\beta$ -1a in Treatment of Severe COVID-19. *Antimicrob Agents Chemother* **2020**; :1–14.
  72. Kalil AC, Mehta AK, Patterson TF, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Respir Med* **2021**; 9:1365–1376.
  73. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med* **2020**; 382:1787–1799.
  74. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients with Symptomatic COVID-19: A Randomized Clinical Trial. *JAMA - J Am Med Assoc* **2020**; 324:2292–2300.
  75. Reis G, dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. *Lancet Glob Heal* **2022**; 10:e42–e51.
  76. Fluvoxamine for early treatment of COVID-19: the STOP COVID clinical trials. 2022. Available at: <https://rethinkingclinicaltrials.org/news/august-20-2021-fluvoxamine-for-early-treatment-of-covid-19-the-stop-covid-clinical-trials-eric-lenze-md/>.
  77. Rao V, Hagen AA, Patel B, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. **2022**;
  78. Yu LM, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *Lancet* **2021**; 398:843–855. Available at: [http://dx.doi.org/10.1016/S0140-6736\(21\)01744-X](http://dx.doi.org/10.1016/S0140-6736(21)01744-X).
  79. Ramakrishnan S, Nicolau D V., Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. *Lancet Respir Med* **2021**; 9:763–772. Available at: [http://dx.doi.org/10.1016/S2213-2600\(21\)00160-0](http://dx.doi.org/10.1016/S2213-2600(21)00160-0).
  80. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents* **2020**; 56:105949. Available at: <https://doi.org/10.1016/j.ijantimicag.2020.105949>.
  81. Mehra MR, Ruschitzka F, Patel AN. Retraction—“Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis” (*The Lancet*, (S0140673620311806), (10.1016/S0140-6736(20)31180-6)). *Lancet* **2020**; 395:1820. Available at: [http://dx.doi.org/10.1016/S0140-6736\(20\)31324-6](http://dx.doi.org/10.1016/S0140-6736(20)31324-6).
  82. Mahévas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: Observational comparative study using routine care data. *BMJ* **2020**; 369:1–9.
  83. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients

- with Covid-19. *N Engl J Med* **2020**; 382:2411–2418.
84. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State. *JAMA - J Am Med Assoc* **2020**; 323:2493–2502.
  85. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial. *BMJ* **2020**; 369:1–11.
  86. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* **2020**; 383:2030–2040.
  87. Doi Y, Hibino M, Hase R, et al. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. *Antimicrob Agents Chemother* **2020**; 64:1–9.
  88. Ivashchenko AA, Dmitriev KA, Vostokova N V., et al. AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. *Clin Infect Dis* **2021**; 73:531–534.
  89. Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. *BMC Infect Dis* **2021**; 21:1–13.
  90. Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. *Sci Immunol* **2020**; 5.
  91. CORIMUNO-19 Collaborative Group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. *Lancet Respir Med* **2021**; 9:295–304.
  92. Temesgen Z, Burger C, Baker J, et al. S48 Lenzilumab efficacy and safety in newly hospitalized Covid-19 subjects: results from the LIVE-AIR phase 3 randomized double-blind placebo-controlled trial. **2021**; :A34.1-A34.
  93. Albertus Beishuizen J, Bocca Ruiz X, Boughanmi H, et al. A Randomized Trial of Otilimab in Severe COVID-19 Pneumonia (OSCAR). *medRxiv* **2021**; :1–36.
  94. Cremer PC, Abbate A, Hudock K, McWilliams C, Mehta J, Chang SY, Sheng CC, Van Tassell B, Bonaventura A, Vecchié A, Carey B, Wang Q, Wolski KE, Rajendram P, Duggal A, Wang TS, Paolini JF TB. MASH-COVID study group. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. *Lancet Rheumatol* **2022**; 3:e410–e418.
  95. Pérez-Martínez A, Mora-Rillo M, Ferreras C, et al. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). *EClinicalMedicine* **2021**; 39.
  96. Shi L, Yuan X, Yao W, et al. Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. *eBioMedicine* **2022**; 75:1–14.
  97. Shi L, Huang H, Lu X, et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. *Signal Transduct Target Ther* **2021**; 6.
  98. López-Medina E, López P, Hurtado IC, et al. Effect of Ivermectin on Time to Resolution of Symptoms among Adults with Mild COVID-19: A Randomized Clinical Trial. *JAMA - J Am Med*

- Assoc **2021**; 325:1426–1435.
99. Lim SCL, Hor CP, Tay KH, et al. Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities. *JAMA Intern Med* **2022**; :1–10.
  100. Seet RCS, Quek AML, Ooi DSQ, et al. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. *Int J Infect Dis* **2021**; 106:314–322. Available at: <https://doi.org/10.1016/j.ijid.2021.04.035>.
  101. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *N Engl J Med* **2020**; 383:517–525.
  102. Bartoszko JJ, Siemieniuk RAC, Kum E, et al. Prophylaxis against covid-19: Living systematic review and network meta-analysis. *BMJ* **2021**; 373:1–12.
  103. Susanna Naggie, Aaron Milstone, Mario Castro, Sean P. Collins, Lakshmi Seetha, Deverick J. Anderson, Lizbeth Cahuayme-Zuniga, Kisha Batey Turner, Lauren W. Cohen, Elizabeth Fraulo, Anne Friedland, Jyotsna Garg, Anoop George, Hillary Mulder, Rachel E. Olso AFH. Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial (HERO-HCQ). *medRxiv* **2021**; :2021.08.19.21262275.
  104. Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: Prophylaxis for hospitalized and nonhospitalized medical patients. *Blood Adv* **2018**; 2:3198–3225.
  105. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. *Chest* **2016**; 149:315–352.
  106. Llitjos JF, Leclerc M, Chochois C et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. *J Thromb Haemost* **2020**; 18:1743–1746. Available at: <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L2004839902%0Ahttp://dx.doi.org/10.1111/jth.14869>.
  107. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. *Intensive Care Med* **2020**; 46:1089–1098. Available at: <https://doi.org/10.1007/s00134-020-06062-x>.
  108. Rosen RJ. Thrombotic complications in critically ill patients with COVID 19. *Thromb Res* **2020**; 191:56.
  109. Tan CW, Fan BE, Teo WZY, et al. Low incidence of venous thrombosis but high incidence of arterial thrombotic complications among critically ill COVID-19 patients in Singapore. *Thromb J* **2021**; 19:1–7.
  110. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J Thromb Haemost* **2020**; 18:1421–1424.
  111. Tan CW, Tan JY, Wong WH, et al. Clinical and laboratory features of hypercoagulability in COVID-19 and other respiratory viral infections amongst predominantly younger adults with few comorbidities. *Sci Rep* **2021**; 11:1–9. Available at: <https://doi.org/10.1038/s41598-021-81166-y>.
  112. Abani O, Abbas A, Abbas F, et al. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* **2022**; 399:143–151.
  113. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. *N Engl J Med* **2021**; 385:777–789.

114. Sadeghipour P, Talasaz AH, Rashidi F, et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality among Patients with COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical. *JAMA - J Am Med Assoc* **2021**; 325:1620–1630.
115. Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. *BMJ* **2021**; 375.
116. Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients with COVID-19: The HEP-COVID Randomized Clinical Trial. *JAMA Intern Med* **2021**; 181:1612–1620.
117. American Society of Hematology. COVID-19 and VTE/Anticoagulation: Frequently Asked Questions. 2022. Available at: <https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation>.
118. Chaudhary R, Bliden KP, Kreutz RP, et al. Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations. *EClinicalMedicine* **2020**; 29–30:100647. Available at: <https://doi.org/10.1016/j.eclinm.2020.100647>.
119. Lee LH, Gallus A, Jindal R, Wang C, Wu CC. Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review. *Thromb Haemost* **2017**; 117:2243–2260.
120. Nishimoto Y, Yachi S, Takeyama M, et al. The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study. *J Cardiol* **2022**; Available at: <https://doi.org/10.1016/j.jjcc.2022.03.015>.
121. NIH. COVID-19 Treatment Guidelines: Special Considerations in Children. Available at: <https://www.covid19treatmentguidelines.nih.gov/special-populations/children/>.
122. Saad AF, Chappell L, Saade GR, Pacheco LD. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19). *Obstet Gynecol* **2020**; 136:823–826.
123. Camprubí D, Gaya A, Marcos MA, et al. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir. *Int J Infect Dis* **2021**; 104:379–381. Available at: <https://doi.org/10.1016/j.ijid.2020.12.050>.
124. Nussenblatt V, Roder AE, Das S, et al. Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion. *J Infect Dis* **2022**; 225:1118–1123.
125. Malin JJ, Cristanziano V Di, Horn C, et al. SARS-CoV-2–neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma. *Blood Adv* **2022**; 6:1580–1584.
126. Furlan A, Forner G, Cipriani L, et al. COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge. *Front Immunol* **2021**; 12.

**4. Key Drug Summary Table** (Note: Therapy should be guided by an Infectious Diseases Physician or by established institutional protocols in consultation with Infectious Diseases)

Medication	Class	Adult Dose with normal renal/hepatic function	Notes (Please see full product information leaflet/drug use guide)
<b>Antivirals</b>			
Remdesivir	RNA-dependent RNA polymerase inhibitor	200 mg IV loading dose, followed by 100 mg IV daily for 5 to 10 days	Timing of antiviral initiation may be important, as administration with high viral loads seen after peak viral titre has been found to fail in reducing lung damage despite reducing viral loads. Early therapy may be more beneficial compared to later therapy. May cause LFT abnormalities/hepatitis. Monitor LFTs prior to initiation and regularly while on remdesivir.
Nirmatrelvir/ritonavir	Protease inhibitors	Nirmatrelvir 300 mg / Ritonavir 100 mg BD for 5 days	<b>If GFR 30-60 ml/min: DOSE REDUCE to Nirmatrelvir 150 mg/ Ritonavir 100 mg BD</b> <b>If GFR &lt;30 ml/min: Use is CONTRAINDICATED</b> <b>Not recommended for use in severe hepatic impairment (Child-Pugh Class C)</b> Numerous interactions with drugs which depend on CYP3A for clearance or which induce CYP3A4 <b>Please consult a drug-interaction database (e.g. Liverpool COVID-19 drug interaction site : <a href="https://www.covid19-druginteractions.org/checker">https://www.covid19-druginteractions.org/checker</a>)</b> Do not crush/break tablets
Molnupiravir	Mutagenesis - induced Inhibition of replication by RNA-dependent RNA polymerase inhibitor	800 mg every 12 hours for 5 days	Do not use in women of childbearing age who cannot avoid pregnancy or who are pregnant or breast feeding. Avoid pregnancy for 4 days after the last dose of molnupiravir (for females) and for at least 3 months after last dose of molnupiravir (for males). Do not use in patients < 18 years of age due to effect on bone/cartilage growth. Special access route as drug is currently not HSA-registered.
<b>Immunomodulators</b>			
Dexamethasone	Steroid	6 mg PO or IV for up to 10 days	If dexamethasone is unavailable, may consider substitution with equivalent daily doses of another corticosteroid (e.g. oral prednisolone 40 mg daily, IV methylprednisolone 32 mg daily or IV hydrocortisone 50mg q8 hours) Dexamethasone is not recommended for patients without hypoxemia, or not requiring oxygen. Caution in patients with concurrent infections. Monitor for hyperglycaemia, psychiatric effects, gastrointestinal bleeding, sepsis and heart failure. Please see also <b>Special populations: Paediatric patients and pregnant women</b> for recommendations in paediatric and pregnancy.
Baricitinib	JAK inhibitor	4mg PO once daily, for up to 14 days	Serious venous thrombosis, including pulmonary embolism, and serious infections have been observed. Prophylaxis for VTE is recommended unless contraindicated. Monitor LFTs and FBC prior to initiation and regularly while on baricitinib.

			Not recommended for patients with known active tuberculosis infections, who are on dialysis, have end-stage renal disease, or have acute kidney injury.
Tofacitinib	JAK inhibitor	10 mg twice daily for up to 14 days	Serious venous thrombosis, including pulmonary embolism, and serious infections have been observed. Prophylaxis for VTE is recommended unless contraindicated. Dose reduce to 5 mg twice daily in moderate to severe renal or hepatic impairment Patients receiving tofacitinib are at increased risk of serious infections which may result in fatality, Not recommended in patients with other concurrent chronic or recurrent infections, lymphoma and other active malignancies requiring treatment.
Tocilizumab	IL-6 inhibitor	8 mg/kg IV ONCE (up to maximum of 800mg per dose). A repeat dose may be given after 12-24 hours.	Consider discussion with Rheumatology-Allergy-Immunology/Intensive Care Physicians for complex cases. Tocilizumab, in particular in combination with corticosteroids, may increase the risk of opportunistic infections or reactivation and lower intestinal perforation. Some experts recommend prophylactic treatment with ivermectin for patients who are from areas where strongyloidiasis is endemic.
<b>Viral-neutralising, antibody-based therapies</b>			
Sotrovimab	Monoclonal antibody to SARS-CoV-2 spike protein	1000 mg IV single dose infusion	Administer as a single IV infusion over 60 minutes; must not be administered as an intravenous push or bolus. Patients should be monitored during and for at least 1 hour after infusion is complete. Anaphylaxis has been reported. If occurs, immediately discontinue administration and initiate appropriate therapy. Infusion-related reactions have been reported. If occurs, consider slowing or stopping the infusion along with appropriate supportive care.
Tixagevimab-cilgavimab	Monoclonal antibody to SARS-CoV-2 spike protein	Prophylaxis: 300 mg Tixagevimab/ 300 mg Cilgavimab  Treatment: 300 mg Tixagevimab/ 300 mg Cilgavimab, IM as two injections	Administered as two separate consecutive intramuscular injections (gluteal). Patients should be monitored during and for at least 1 hour after infusion is complete.

\*LFT=Liver function tests, VTE = Venous thromboembolism

## Annex A: Data on various Monoclonal Antibodies (Mab) and activity against SARS-CoV-2

**Table 1. Stanford Database - <https://covdb.stanford.edu/susceptibility-data/table-mab-susc/>: Virus variants and spike mutations vs monoclonal antibodies: Fold reduced neutralizing susceptibility to monoclonal antibodies under Emergency Use Authorization (EUA) [c.a.a. 15 August 2022]**

The color scheme indicates the fold-reduction in neutralization: **absence of color** – <5-fold reduced susceptibility; **light blue** – 5 to 24.9-fold reduced susceptibility; **dark blue** – ≥25-fold reduced susceptibility.

Test\mAb	CAS	IMD	CAS/IMD	CIL	TIX	CIL/TIX	SOT	BEB
Alpha	1 <sub>32</sub>	0.7 <sub>33</sub>	1 <sub>15</sub>	0.6 <sub>13</sub>	1.5 <sub>13</sub>	0.9 <sub>12</sub>	2 <sub>26</sub>	0.9 <sub>6</sub>
Beta	72 <sub>37</sub>	0.6 <sub>37</sub>	1.6 <sub>19</sub>	1.1 <sub>13</sub>	5.8 <sub>15</sub>	2 <sub>13</sub>	1.0 <sub>26</sub>	1 <sub>7</sub>
Gamma	124 <sub>24</sub>	0.4 <sub>24</sub>	1 <sub>9</sub>	0.5 <sub>11</sub>	3.7 <sub>11</sub>	0.9 <sub>8</sub>	1 <sub>21</sub>	1 <sub>5</sub>
Delta	0.7 <sub>29</sub>	2.1 <sub>30</sub>	1 <sub>11</sub>	2.5 <sub>12</sub>	1 <sub>13</sub>	1 <sub>13</sub>	1.3 <sub>23</sub>	1 <sub>11</sub>
Omicron/BA.1	>1000 <sub>43</sub>	>1000 <sub>44</sub>	>1000 <sub>17</sub>	268 <sub>35</sub>	273 <sub>41</sub>	76	3.8 <sub>49</sub>	1 <sub>18</sub>
Omicron/BA.2	>1000 <sub>25</sub>	181 <sub>22</sub>	387 <sub>13</sub>	2.1 <sub>23</sub>	749 <sub>22</sub>	7.8 <sub>18</sub>	18 <sub>31</sub>	1.1 <sub>19</sub>
Omicron/BA.2.12.1	>1000 <sub>5</sub>	88 <sub>8</sub>	143 <sub>5</sub>	3.3 <sub>6</sub>	382 <sub>6</sub>	9.5 <sub>5</sub>	26 <sub>8</sub>	0.9 <sub>6</sub>
Omicron/BA.4/5	>1000 <sub>10</sub>	586 <sub>10</sub>	410 <sub>6</sub>	9.3 <sub>10</sub>	>1000 <sub>10</sub>	23 <sub>8</sub>	18 <sub>11</sub>	1.1 <sub>8</sub>
Omicron/BA.2.75	91 <sub>3</sub>	625 <sub>3</sub>	541 <sub>3</sub>	34 <sub>3</sub>	30 <sub>3</sub>	54 <sub>3</sub>	10 <sub>3</sub>	6 <sub>3</sub>

Monoclonal antibody(mAb) abbreviations: CAS: Casirivimab/REGN10933, IMD: Imdevimab/REGN10987, CIL: Cilgavimab/COV2-2130/AZD1061, TIX: Tixagevimab/COV2-2196/AZD8895, SOT: Sotrovimab/Vir-7831/S309, BEB: Bebtelovimab/LY-CoV1404/LY3853113

**Table 2: Neutralisation of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies - 50% neutralisation concentration (ng/mL)** Data from: Yamasoba D, et al. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022 Jul;22(7):942-943. doi: 10.1016/S1473-3099(22)00365-6. Epub 2022 Jun 9. PMID: 35690075; PMCID: PMC9179126. **(Lentivirus pseudovirus study)**

	BEB	CAS	CIL	IMD	SOT	TIX	CAS/IMD	CIL/TIX
B.1.1 (parental)	8.1	9.9	21	79	94	6.7	6.2	4.1
BA.2	3.8	>50 417	19	>50 000	2190	>2750	>2400	33
BA.2.11	2.3	>50 417	71	>50 000	540	>2750	>2400	154
BA.2.12.1	5.5	>50 417	75	>50 000	629	>2750	>2400	135
BA.4/5	6.3	>50 417	443	>50 000	1261	>2750	>2400	609
BA.2 L452Q	5.0	>50 417	26	>50 000	2443	>2750	>2400	82
BA.2 S704L	1.1	>50 417	28	>50 000	1213	>2750	>2400	27
BA.2 HV69-70del	2.2	>50 417	19	>50 000	774	>2750	>2400	34
BA.2 F486V	1.1	>50 417	18	>50 000	1575	>2750	>2400	23
BA.2 R493Q	4.2	3697	22	>50 000	1791	101	431	31

**Table 3 Neutralizing activity against SARS-CoV-2 variants and sarbecoviruses by therapeutic MABs.**

Data from: Cao Y, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022 Jun 17. doi: 10.1038/s41586-022-04980-y. Epub ahead of print. PMID: 35714668. (VSV pseudovirus study)

	BEB	CAS	IMD	CAS/IMD	SOT	CIL	TIX	CIL/TIX
D614G	0.7	5.6	5.7	5.0	74	2.5	1.6	2.1
BA.1	0.6	*	*	*	361	3007	5419	491
BA.1.1	1.8	8912	*	*	314	*	4764	8090
BA.2	0.9	*	590	821	918	6.3	4312	8.2
BA.3	1.1	*	*	*	972	11	5609	19
BA.2.13	1.0	9221	417	699	700	6.6	3591	7.1
BA.2.12.1	0.8	*	499	714	989	11	5521	18
BA.4/BA.5	0.9	*	520	709	792	23	*	40

**Green**, half-maximal inhibitory concentration ( $IC_{50}$ )  $\leq 30$  ng ml<sup>-1</sup>; white,  $30$  ng ml<sup>-1</sup> <  $IC_{50}$  <  $1,000$  ng ml<sup>-1</sup>; **red**,  $IC_{50} \geq 1,000$  ng ml<sup>-1</sup>; \*,  $IC_{50} \geq 10,000$  ng ml<sup>-1</sup>. All neutralization assays were performed as biological duplicates

**Table 4. Efficacy of Monoclonal Antibodies against Omicron Subvariants in Vitro**

Data from : Takashita E, et al Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N Engl J Med. 2022 Aug 4;387(5):468-470. doi: 10.1056/NEJMc2207519. Epub 2022 Jul 20. PMID: 35857646; PMCID: PMC9342381. (Omicron subvariant virus isolates)

Subvariant	Mean Neutralization Activity of Monoclonal Antibody <sup>†</sup>							
	IMD	CAS	TIX	CIL	SOT precursor	BEB	CAS/IMD	TIX/CIL
	ng per milliliter							
Reference <sup>§</sup>	7.4	6.1	6.1	7.0	95.1	2.5	3.4	6.3
BA.1	>50,000	>50,000	1552.7	2916.9	40727.1	5.8	>10,000	351.1
BA.1.1	>50,000	>50,000	603.5	>50,000	3769.2	3.9	>10,000	1296.8
BA.2	329.0	>50,000	2756.6	16.9	>50,000	3.3	835.1	34.6
BA.2.12.1	238.1	>50,000	335.2	21.0	>50,000	4.0	452.7	38.1
BA.4	132.6	>50,000	>50,000	53.6	>50,000	2.9	459.1	37.8
BA.5	583.4	>50,000	>50,000	56.8	>50,000	3.3	1093.1	192.5

<sup>†</sup>Individual monoclonal antibodies were tested at a starting concentration of 50,000 ng per millilitre on 50% focus reduction neutralization testing. The monoclonal antibody combinations were tested at a starting concentration of 10,000 ng per millilitre for each antibody.

<sup>§</sup>The reference strain was SARS-CoV-2/UT-NC002-1T/Human/2020/Tokyo.

**Annex B: Immunocompromise Definitions – following EC19V (Expert Committee on COVID-19 Vaccination)**

**Immunocompromised (Follows EC19V Definition)\*:**

- a. Transplant patients on medications that suppress the immune system, including solid organ and allogenic stem cell transplants
- b. Cancer patients on active treatment with chemotherapy or on other therapies that suppress the immune system
- c. Haematological cancers
- d. Non-cancer conditions that suppress the immune system#
- e. End-stage kidney disease (*i.e. on haemodialysis or peritoneal dialysis*)
- f. Advanced or untreated HIV

*\*Less likely to mount an immune response to vaccination and more likely to have poor outcome from severe COVID-19*

*# Including patients on treatments which suppress the immune system (e.g. Active treatment with high-dose corticosteroids (e.g.,  $\geq 20$  mg prednisone or equivalent per day when administered for  $\geq 2$  weeks), alkylating agents, antimetabolites, tumour-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents)) or those with moderate or severe primary immunodeficiencies.*

## Annex C: Algorithm for consideration of oral antivirals

### Patient must fulfil **ALL** the following **BASE ELIGIBILITY** criteria:

- Y Within 5 days of onset of symptoms [must be symptomatic]
- Y Test-confirmed COVID-19 (PCR or Antigen Test Positive)
- Y ≥18 years old
- Y Does not have severe disease (e.g. hypoxic, SpO<sub>2</sub> < 94%)

NB: The option of careful observation/reassessment without OAV therapy may be reasonable if patient is clinically well and fully vaccinated, immunocompetent, with no concern for pneumonia (e.g. normal exam or chest X-ray) and CRP <20 mg/L (if available)

**YES & treatment being considered**

### Patient must have **1 or more of the following RISK FACTORS** for severe COVID\*:

- Y Age (≥60 regardless of vaccine status)
  - Y Active cancer
  - Y BMI ≥25 kg/m<sup>2</sup> (unvaccinated)
  - Y BMI ≥30 kg/m<sup>2</sup> (vaccinated)
  - Y Chronic Kidney Disease (CKD)
  - Y Chronic obstructive lung disease
  - Y Serious heart conditions (Heart failure, coronary artery disease, cardiomyopathies)
  - Y Poorly controlled diabetes mellitus/ with end-organ involvement
  - Y Ongoing immunosuppressive condition/ treatment
- \* Patients with 1 or more of the above risk factors and who have clinical or radiographic evidence of pneumonia (if available) or a CRP ≥ 50 mg/L (if available) should be prioritised for treatment

**YES**

### Does the patient have **any of the following CONTRAINDICATIONS** to Paxlovid?

- Significant drug-drug interactions that cannot be adjusted for
- GFR < 30ml/ min
- Severe hepatic impairment (Child-Pugh Class C)(Not recommended, insufficient data)

**NO**  
contraindications to  
Paxlovid

**PAXLOVID should be considered as the 1<sup>st</sup> line (default) OAV treatment**

**YES there are**  
contraindications  
to Paxlovid

#### **MOLNUPIRAVIR** may be considered if:

- Y Unvaccinated and/or;
- Y Anticipated poor response to vaccination e.g. CKD, transplant or other immunocompromised patients, and/or
- Y Concern for pneumonia

**NB: Patient must not be pregnant or breastfeeding**

*If none of the above criteria, may consider not prescribing any OAVs and careful observation, given the lower efficacy of molnupiravir.*

## Annex D: Managing Common Drug-Drug Interactions with Nirmatrelvir/Ritonavir (Paxlovid)

\*Please note list is not exhaustive. Please consult a drug-interaction database (e.g. [www.covid19-druginteractions.org](http://www.covid19-druginteractions.org)) or pharmacist if required.

Class	Drugs	Recommendations
<b>Antimicrobials</b>		
<b>Antibiotics</b>	Rifampicin	Coadministration is <b>contraindicated</b> ; may cause large decreases in paxlovid concentrations and significantly decrease its therapeutic effect. Due to the persisting inducing effect upon discontinuation of a strong inducer, <b>consider an alternative COVID-19 treatment.</b>
	Rifabutin	Coadministration may increase exposure of rifabutin. It is recommended to give rifabutin 150 mg every day in presence of paxlovid; can return to usual dose 3 days after completion of paxlovid
<b>Anti-retrovirals</b>	Protease inhibitors	No dose adjustments necessary (even if on ritonavir/cobicistat boosted regimen) monitor for protease inhibitor adverse effects. Patients should be informed about the potential occurrence of gastrointestinal side effects (e.g. diarrhoea) due to the higher dose of ritonavir
<b>Central nervous system drugs</b>		
<b>Anticonvulsants</b>	Carbamazepine	Strong CYP inducers - <b>coadministration is contraindicated.</b> Decreased plasma concentrations of paxlovid may lead to loss of virologic response and possible resistance. Cannot be started immediately after discontinuation of anticonvulsant due to the delayed offset of the recently discontinued CYP3A inducer.
	Phenobarbital	
	Phenytoin	
<b>Antipsychotic</b>	Aripiprazole	Paxlovid could potentially increase aripiprazole concentrations. <b>Monitor adverse effects and decrease aripiprazole dosage if needed.</b> The decision to modify the dosage should be done in consultation with a specialist in mental health medicine. After stopping paxlovid, can resume previous dose after 3 days.
	Clozapine	Coadministration may increase clozapine concentrations. <b>Co-administration contraindicated</b> due to serious and/or life-threatening reactions (i.e., serious haematological abnormalities)
	Quetiapine	Coadministration may increase quetiapine concentrations and is <b>not recommended.</b> If coadministration is necessary, US product label recommends to reduce quetiapine dose to

		one sixth the normal dose and monitor for quetiapine associated adverse reactions. Refer to the quetiapine prescribing information for detailed recommendations . To resume old dose/restart quetiapine 3 days after last dose of paxlovid
<b>Benzodiazepines</b>	Alprazolam	Consider a lower dose of alprazolam used cautiously and monitor for adverse effects. After stopping paxlovid, resume old dose 3 days after last dose
	Clonazepam	Coadministration is <b>contraindicated</b> . May increase concentrations and increase the risk of extreme sedation and respiratory depression. <b>Can resume 3 days after completing paxlovid.</b>
	Diazepam	
	Midazolam (Oral)	
	Midazolam (IV)	Coadministration of paxlovid and PARENTERAL midazolam should be done with caution and in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. <b>Dosage reduction for IV midazolam should be considered, especially if more than a single dose of midazolam is administered.</b>
Lorazepam	<b>No dose adjustment is required</b>	
<b>Cardiac and related</b>		
<b>Anti-arrhythmic</b>	Amiodarone	Coadministration is <b>contraindicated</b> . Potentially increased plasma concentrations of antiarrhythmics may result in arrhythmias or other serious adverse effects. <b>Consider an alternative COVID-19 treatment.</b>
	Flecainide	
	Propafenone	
	Quinidine	
<b>Calcium channel blockers</b>	Amlodipine	May increase plasma concentrations of calcium channel blockers. <b>A dose reduction may be considered</b> (but is optional), to monitor for symptoms of hypotension and to temporarily pause the antihypertensive drug if needed. To <b>resume dose 3 days after</b> completion of paxlovid
	Nifedipine	
	Diltiazem	
	Verapamil	

<b>Alpha-1 blockers</b>	Alfuzosin	Coadministration may increase alfuzosin concentrations which may result in severe hypotension. Given the short duration of paxlovid treatment, alfuzosin should be stopped. To resume 3 days after the last dose of paxlovid.
	Tamsulosin	Coadministration may increase tamsulosin exposure. Given tamsulosin's higher affinity for alpha-1A receptors located in prostatic smooth muscle and its demonstrated tolerability when combined with other CYP3A4/CYP2D6 inhibitors, coadministration can be considered. Patients should be advised to monitor for signs/symptoms of hypotension and to watch their blood pressure. Tamsulosin may be stopped for the duration of paxlovid treatment if symptomatic hypotension occurs.
	Terazosin	Coadministration may increase terazosin levels due to inhibition of CYP3A4. Given short duration of paxlovid treatment, no dose adjustment is recommended. Patients should be advised to monitor for signs/symptoms of hypotension and to watch their blood pressure. Terazosin may be stopped for the duration of paxlovid treatment if symptomatic hypotension occurs.
	Prazosin	Prazosin is metabolised primarily via demethylation and conjugation, and possibly to a lesser extent via CYP enzymes. Given short duration of paxlovid treatment, no dose adjustment is recommended.
<b>Direct oral anticoagulants</b>	Rivaroxaban	Potentially increased concentrations of anticoagulants which may lead to an increased bleeding risk. <b>Concomitant use with Paxlovid is not recommended.</b> The management of this interaction should also take into account the <b>indication of the anticoagulation</b> and whether or not NOACs can be stopped during the course of paxlovid treatment. If withheld, it should be <b>resumed 3 days after</b> last dose of paxlovid.
	Apixaban	
	Dabigatran	
<b>Warfarin</b>	-	Coadministration is expected to decrease warfarin concentrations. Closely monitor INR if coadministration with warfarin is necessary. If close INR monitoring is not possible, consider alternate COVID-19 therapy.
<b>Antiplatelets</b>	Clopidogrel	Coadministration with paxlovid is likely to reduce the effect of clopidogrel. The management of this interaction requires to <b>take into account whether or not a transient loss of clopidogrel efficacy during the short duration</b> of paxlovid treatment is acceptable. <b>Consider alternative covid-19 treatment in patients at very high-risk of thrombosis, e.g. at least within 6 weeks of coronary stenting.</b>
	Ticagrelor	Coadministration is <b>contraindicated</b> as it may lead to a substantial increase in exposure to ticagrelor. Prasugrel can be used with paxlovid unless the patient has a clinical

		condition which contraindicates its use in which case an alternative antiplatelet agent should be considered
<b>PDE5 inhibitors</b>	Sildenafil	Coadministration is <b>contraindicated</b> when used for the treatment of pulmonary arterial hypertension. Increased plasma concentrations of PDE5 inhibitors can potentially result in visual abnormalities, hypotension, prolonged erection and syncope.
	Tadalafil	
<b>HMG-CoA reductase inhibitors</b>	Lovastatin	Coadministration with potent CYP3A4 inhibitors, such as ritonavir, is <b>contraindicated</b> due to the high risk of presenting serious reactions such as risk of myopathy including rhabdomyolysis. <b>To stop temporarily and resume 3 days after the last dose of paxlovid</b>
	Simvastatin	
	Atorvastatin	Less dependent on CYP3A for metabolism. When used with paxlovid, <b>the lowest possible doses of statin should be administered.</b> Given the short duration of nirmatrelvir/ritonavir treatment, <b>can consider withholding these statins</b> as well, and to resume 3 days after completion of paxlovid. .
	Rosuvastatin	
<b>Ivabradine</b>	-	Co-administration contraindicated as ivabradine concentrations will increase and this is associated with the risk of bradycardia.
<b>Cardiac glycosides</b>	Digoxin	Co-administration may increase digoxin concentrations. Caution should be exercised when co-administering PAXLOVID with digoxin, with <b>appropriate monitoring of serum digoxin levels.</b> Refer to the digoxin product label for further information
<b>Immunosuppressants and pulmonary</b>		
<b>Corticosteroids (oral/parenteral)</b>	-	Given short duration of Paxlovid, this interaction is unlikely to be clinically significant. No dose change required.
<b>Inhaled corticosteroids</b>	<b>Budesonide</b>	<b>No specific action needed.</b> Co-administration may increase corticosteroid concentrations. Increased risk for Cushing's syndrome and adrenal suppression. Unlikely clinically relevant due to short treatment duration of Paxlovid (triamcinolone may present a higher risk compared to other corticosteroids due to its long half-life and high potency) – to monitor
	Fluticasone	
	Triamcinolone	
<b>Salmeterol</b>	-	Coadministration may increase salmeterol concentrations, which may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia. Therefore, <b>concomitant use is not recommended.</b>

<b>Immunosuppressants</b>	Cyclosporine	Increases plasma concentrations of immunosuppressants which rapidly reach toxic levels. Therapeutic concentration monitoring is recommended for immunosuppressants. <b>Avoid use of PAXLOVID when close monitoring of immunosuppressant serum concentrations is not feasible.</b> If co-administered, refer to individual product label for immunosuppressant for further information. Considering the complex management of this interaction, <b>an alternative COVID treatment will need to be considered.</b>
	Tacrolimus	
	Sirolimus	
<b>Miscellaneous</b>		
<b>Colchicine</b>	-	Co-administration <b>contraindicated</b> due to potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment
<b>Herbal products</b>	St. John's Wort ( <i>Hypericum perforatum</i> )	Co-administration <b>contraindicated</b> due to potential loss of virologic response and possible resistance

## **COVID-19 Therapeutic Workgroup**

**Dr Shawn Vasoo (ID) – NCID – Clinical Director, Chair**

**Dr Barnaby Young (ID), NCID – Deputy Chair**

**Dr Asok Kurup (ID) – Chapter ID, AMS, Chair**

**A/Prof Tan Thuan Tong (ID) - SGH – Head, ID**

**A/Prof Sophia Archuleta (ID) - NUH , Head ID**

**A/Prof David Lye (ID/Clinical Trials) – NCID**

**Prof David Allen (ID) – NUHS / NCID**

**A/Prof Bernard Thong (Rheumatology/Allergy/Immunology) – TTSH**

**Dr Howe Hwee Siew (Rheumatology/Allergy/Immunology) – TTSH**

**A/Prof Andrea Kwa (Pharmacy) – SGH**

**Ms Law Hwa Lin (Pharmacy) – NCID, Pharmacy Head of Service**

**Ms Grace Hoo (Pharmacy) – NCID**

**Dr Kee Ya Ling (Pharmacy) - NCID**

**A/Prof Raymond Lin (Virology) - NPHL**

**Dr Lisa Tan – HSA Director, Innovation Office & Clinical Trials Branch**

**Dr Ong Kiat Hoe (Haematology)– TTSH**

**Prof Jerry Chan (O&G), KKWCH, Department of Reproductive Medicine**

### **Members of ID Chapter, Academy of Medicine Singapore**

A/Prof Asok Kurup, Chairman

Dr Lee Tau Hong, Vice-Chair

Dr Catherine Ong, Hon. Secretary

A/Prof Brenda Ang, Member

### **Members of COVID-19 Clinical Management Committee (MOH)**

Haematology: Dr Lee Lai Heng, Dr Yap Eng Soo

Paediatrics: Adj A/Prof Thoon Koh Cheng, Dr Chan Si Min

### **Members of Paediatric-Obstetric-Neonatal Outbreak Workgroup**

Dr Sapna Sadarangani, NCID, ID

Dr Thoon Koh Cheng, KKWCH, Paeds ID

Dr Chan Si Min, NUH, Paeds ID